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Summary 
Introduction: The Restless Legs Syndrome (RLS) is a frequent neurological disorder 
with a prevalence ranging from 5 – 10%. RLS is characterized by an urge to move the 
lower extremities during the night, thus RLS causes sleep disturbance. It presents as 
both idiopathic and secondary form. Idiopathic RLS is associated with common 
genetic variants in MEIS1, BTBD9, PTPRD and MAP2K5/SCOR1. Recently, multiple 
sclerosis (MS) was identified as a common cause for secondary RLS, the prevalence 
of RLS in patients with MS ranges from 13.3 to 37.5%.  
The aim of our study was to analyse the clinical and genetic aspects of this disorder, 
especially in patients with multiple sclerosis.  
In the clinical part, we evaluated the prevalence of RLS among Czech patients with 
MS and we compared the extent of brain damage between patients with and without 
RLS using magnetic resonance imaging (MRI). In the genetic part, we further 
analysed the impact of known genetic variants (MEIS1, BTBD9, MAP2K5/SCOR1, 
PTPRD) for RLS in other European populations and in patients with MS. 
Methods: Clinical part: Each patient with MS underwent a semi-structured 
interview. A patient was considered to be affected by RLS if he/she met all four 
standard criteria at life-long interval. Lesion load (LL – T2), brain atrophy – T1 and 
brain parenchymal fraction (BPF) were assessed in some patients. 
Genetic part included two genetic association studies. In the first study, we 
investigated these variants in 649 RLS patients and 1230 controls from the Czech 
Republic, Austria and Finland. Ten SNPs (single nucleotide polymorphisms) within 
the three genomic regions (MEIS1, BTBD9 a MAP2K5/SCOR1) were selected. In the 
second study, 203 MS patients with RLS were compared to 438 MS patients without 
RLS. In total 12 SNPs within the four genomic regions (MEIS1, BTBD9 a 
MAP2K5/SCOR1, PTPRD) were genotyped. 
Results: Clinical part: A total of 765 subjects (553 females, mean age 36.54, ±SD 
9.5) with MS were included in the study. The diagnosis of RLS was confirmed in 245 
subjects (32.1%, 95% CI 28.7 – 35.4%) with MS. Patients suffering from both MS and 
RLS were significantly older (38.6 vs. 35.6 years), had longer durations of MS 
symptoms (11.0 vs. 8.2 years) and had higher EDSS score (2.9 vs. 2.3).  
Quantitative MRI data were obtained in 385 patients without RLS and 215 patients 
with RLS. We found no difference between the two groups in the whole brain LL, 
brain atrophy and BPF, despite the fact that we were able to replicate the correlation of 
these data with clinical parameters of MS. 
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Genetic part: We replicated associations for all loci in the combined samples set 
(MEIS1, P = 1.26x10
-5
, odds ratio (OR) = 1.47, BTBD9, P = 4.11x10
-5
, OR = 1.58 and 
MAP2K5/SCOR1, P = 0.04764, OR = 1.27).  
No significant association with MEIS 1, BTBD9 and PTPRD was found in patients 
with MS despite sufficient statistical power for the first two loci. There was a trend for 
association with MAP2K5/SCOR1 – the best model for the risk allele was the recessive 
model (p nominal = 0.0029, p corrected for four loci and allelic + recessive model = 
0.023, odds ratio = 1.60 – 95% CI 1.17 – 2.18). 
Conclusion: RLS is a common comorbidity of multiple sclerosis and MS should be 
considered among causes of secondary RLS forms. RLS is more prevalent in advanced 
stages of MS, but does not correlate with MRI markers of brain damage.  
Our study confirmed that variants in these three loci (MEIS1, BTBD9, and 
MAP2K5/SCOR1) confer consistent disease risks in patients of European descent. On 
the contrary, RLS in MS patients shares only few genetic determinants with the 




Úvod: Syndrom neklidných nohou (RLS – Restless Legs Syndrome) je časté 
neurologické onemocnění s prevalencí 5 – 10% v evropské populaci. Je 
charakterizované nutkáním pohybovat končetinami a v rozvinuté formě interferuje se 
spánkem. RLS je komplexní dědičné onemocnění, idiopatické formy jsou asociovány 
s variantami genů MEIS1, BTBD9, PTPRD a MAP2K5/SCOR1. Recentní studie 
uvádějí roztroušenou sklerózu jako novou příčinu sekundární formy RLS s prevalencí 
19 – 37,5%. 
Cílem naší práce bylo vyšetřit některé klinické a genetické aspekty tohoto 
onemocnění, hl. u pacientů s roztroušenou sklerózou (RS). V klinické části jsme 
vyšetřovali prevalenci RLS u českých pacientů s RS a porovnávali jsme rozsah 
postižení mozku na magnetické rezonanci (MR) u pacientů s RLS a bez RLS. V 
genetické části jsme zjišťovali, zda známé genetické varianty (MEIS1, BTBD9, 
PTPRD a MAP2K5/SCOR1) zvyšují riziko rozvoje RLS také u jiných evropských 
populací a u pacientů s RS. 
Metodika: V klinické části (epidemiologické studii) byli pacienti s RS dotazováni na 
symptomy RLS; každý pacient absolvoval strukturovaný rozhovor cílený na 
přítomnost základních diagnostických kritérií, rodinnou anamnézu, komorbidity a 
terapii. U některých pacientů (radiologická studie) byla provedena MR mozku se 
zaměřením na objem T2 hyperintenzních ložisek (lesion load – LL), mozkovou atrofii 
a brain parenchymal fraction (BPF). 
Genetická část zahrnuje 2 genetické asociační studie: 1. jsme vyšetřovali přítomnost 
genetických variant u 649 pacientů s idiopatickým RLS a 1230 kontrol ze 3 
evropských populací (ČR, Rakousko, Finsko). 10 SNPs (single nucleotide 
polymorphisms) bylo vybráno na 3 genech (MEIS1, BTBD9 a MAP2K5/SCOR1). Ve 
2. studii jsme porovnávali přítomnost genetických variant u pacientů RS a RLS oproti 
pacientům s RS, ale bez symptomů RLS. Celkem 12 SNPs bylo vybráno na 4 genech 
(MEIS1, BTBD9 a MAP2K5/SCOR1, PTPRD).  
Výsledky: Do epidemiologické studie bylo zahrnuto celkem 765 pacientů s RS (553 
žen, průměrný věk 36.54, ±SD 9.5). Diagnóza RLS byla potvrzena u 245 pacientů 
(32.1%, 95% CI 28.7 – 35.4%). V porovnání s pacienty bez RLS byli pacienti s RLS 
byli signifikantně starší (38.6 vs. 35.6 let), měli delší trvání roztroušené sklerózy (11.0 
vs. 8.2 let) a měli vyšší EDSS skóre (2.9 vs. 2.3). 
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Kvantitativní data z MR (LL, BPF a mozková atrofie) byla porovnána u 385 pacientů 
bez RLS a u 215 pacientů s RLS, nebyl nalezen signifikantní rozdíl mezi pacienty s 
RLS a bez tohoto onemocnění, ačkoli jsme prokázali korelaci mezi uvedenými 
parametry a tíží RS. 
V genetické části jsme replikovali asociaci všech lokusů v kombinovaném vzorku 3 
populací (MEIS1, P = 1.26x10
-5
, odds ratio (OR) = 1.47, BTBD9, P = 4.11x10
-5
, OR = 
1.58, MAP2K5/SCOR1, P = 0.04764, OR = 1.27). Ve studii s RS byl nalezen trend pro 
asociaci u SCOR1, nejlepším modelem pro tuto variantu byl recesivní model (p nom = 
0.0029, p korigované pro model a 4 geny = 0.023, genotypické OR = 1.60 – 95% CI 
1.17 – 2.18). Nebyla prokázána asociace s variantami MEIS1 a BTBD9 i přes 
dostatečnou statistickou sílu.  
Závěr: Syndrom neklidných nohou je častou komorbiditou roztroušené sklerózy 
(prevalence 32%), může nepříznivě ovlivňovat kvalitu spánku a RS by měla být 
zahrnuta mezi sekundární formy RLS. RLS je častější v rozvinuté formě RS, ale 
nekoreluje s mírou postižení mozku na magnetické rezonanci.  
Genetická studie s idiopatickým RLS potvrdila význam variant v intronických a 
intergenových oblastech MEIS1, BTBD9 a MAP2K5/SCOR1 v české, rakouské a 
finské populaci. Naopak RLS u pacientů s RS sdílí tedy jen malou část rizikových 
genetických faktorů s formami idiopatickými, varianta SCOR1 přispívá k fenotypu z 




Restless legs syndrome (RLS) is a common neurological disorder. The disease is 
characterized by an imperative urge to move the legs associated with unpleasant 
sensations in the lower limbs. Symptoms typically occur at rest in the evening and at 
night and RLS is often associated with periodic limb movement in sleep (PLMS), thus 
RLS can lead to sleep disturbance and impaired quality of life in its developed form. 
Sleep disturbance typically involves initiating and maintaining sleep (1).  
RLS is one of the commonest neurological sensorimotor disorders at least in Western 
countries, the prevalence in the European population ranges from 5% to 10%. 
However, it remains largely underdiagnosed and undertreated (2). 
International Classification of Sleep Disorders – ICSD2 classes RLS as sleep related 
movement disorder. The term “restless legs syndrome” was first used by Karl Ekbom 
in 1945 (3). 
 
Symptoms, clinical description and course, diagnosis:  
RLS is typically characterised by an urge to move the limbs, accompanied by 
uncomfortable and unpleasant sensations in the legs.  
The diagnosis of RLS is clinical and is based on the patient`s description. Subjective 
symptoms were first described by Thomas Willis in the 17th century and an extensive 
description of the disease was made by Ekbom in 1945, thus the condition is also 
referred to as Willis-Ekbom disease. The diagnostic criteria for RLS were established 
in 1995 by the IRLSSG (International RLS Study Group) and modified in 2003 (1). 
Accordingly, four essential criteria are required to establish the diagnosis of RLS. 
 
1) an urge to move the legs, usually accompanied or caused by uncomfortable and 
unpleasant sensations in the legs 
 
2) an urge to move or unpleasant sensations begin or worsen during period of rest 
or inactivity such as lying or sitting 
 
3) an urge to move or unpleasant sensations are partially or totally relieved by 
movement, such as walking or stretching, at least as long as the activity continues 
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4) an urge to move or unpleasant sensations are worse in the evening or at night 
than during the day or only occur in the evening or at night (when symptoms are 
very severe, the worsening at night may not be noticeable but must have been 
previously present). 
 
A family history of RLS, a positive response to dopaminergic treatment, and an 
association with periodic limb movements in sleep (PLMS) are additional clinical 
features that may provide support for the diagnosis in some atypical clinical 
presentations (4-6).  
RLS suffers present with a wide range of sensory and motor symptoms. The sensory 
symptoms include different unpleasant sensations (dysesthesia, paresthesia) such as 
tingling, burning, pricking, itching, leg cramps etc. and even pain in some cases. The 
legs are mostly affected, the disorder may also involve the arms and other body parts 
(7). There is often bilateral involvement but symptoms can be asymmetrical. The 
motor restlessness is another clinical feature, patients suffer from an urge to move, 
some people are unaware of a sensory component. Eighty percent of patients develop 
periodic limb movement in sleep (PLMS) (4, 8). 
RLS usually begins or worsens during the period of inactivity (watching television, 
driving a car, during lectures etc.). Symptoms are relieved by activity such as flexing, 
stretching or walking. In most patients the relief is complete, but patients with severe 
RLS report only partial improvement. RLS has a typical circadian pattern with the 
maximum of symptoms in the evening and during the night resulting in insomnia (6, 
9). Most patients report difficulty falling asleep and night awakenings. Studies with 
polysomnography showed prolonged sleep latency, reduced sleep efficiency and total 
sleep time (5, 10, 11). Several patients also complain about excessive daytime fatigue 
and sleepiness. Clinical course is variable from one patient to another, in one patient 
during the time and within the family. RLS can begin at any age and childhood cases 
have been reported. However, the majority of patients seen in clinical practice are 
middle aged or older. Patients with early onset (before age 45) tend to have slower 
progression milder, symptoms and strong family history, those with late onset show a 
more rapid progression (12). 
RLS diagnosis is based on clinical description, four diagnostic criteria can be easily 
confirmed by history. An interview with a trained physician is necessary for the 
correct diagnosis, if only questionnaires with RLS criteria are given this results in 
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approximately 10 – 25% false positive cases due to “RLS mimics” (13). Patients with 
RLS mimics meet all essential criteria but do not actually have RLS; important mimics 
include akathasia, positional discomfort, cramps and anxiety disorder. RLS also needs 
to be differentiated from other conditions that can also coexist with RLS (neuropathy, 
multiple sclerosis, etc.). The diagnosis in the childhood, when a clear verbal 
description cannot be given, can be supported by a positive family history or 
polysomnography (PLM index) (14). 
The performance of routine laboratory tests such as renal function, thyroid parameters, 
red blood cell count, iron status and physical examination are considered standard in 
RLS and are used to diagnose secondary RLS. Iron status involves measures of iron, 
serum ferritin and transferring saturation (14). Polysomnography is not required in all 
RLS patients, but useful in patients with other sleep related disorders. 
Polysomnography can be used as a supportive diagnostic tool and as an objective 
means of assessing treatment response and disease severity in RLS. Actigraphy 
represents an alternative less expensive method for PLMS measurement (15).  
RLS is a heterogeneous disease, whose severity and frequency vary from one patient 
to another. Therefore, although RLS prevalence is rather high, only 3.4% need a drug 
therapy (16). International RLS scale was developed as a scoring system for RLS 
symptom severity by the International RLS Study Group. Dopaminergic agents (L-
DOPA and dopamine agonist) are the first line RLS therapy (17), the major 
complication of this therapy represents augmentation. Augmentation is characterized 
by increasing intensity of symptoms, earlier onset of symptoms in the day, reduced 
time at rest before the symptoms start and spread of symptoms to other body parts. 
(18) 
Morbidity of RLS and quality of life 
RLS affects sleep, mood, health and quality of life. 20% of patients with RLS (3% of 
population) experience clinically and medically significant RLS symptoms – which 
occur at least twice a week and are reported as moderately or severely distressing. In 
these patients, RLS causes insomnia, patients sleep only 4–5 hours and chronic sleep 
loss leads to deficits in daily functions particularly in terms of wakefulness during 
work and social activities (2, 16).   
Several large epidemiological studies have shown significantly decreased quality of 
life (QoL) in RLS patients when compared to the general population. The Medical 
Outcomes Study 36-Item Short Form Health Survey (SF-36), the physical and mental 
summary scores have been widely used to asses health status and quality of life. In SF-
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36, 8 dimensions of health-related quality of life are evaluated: physical functioning, 
physical limitations on normal activities (role-physical), bodily pain, general health 
perceptions, energy and vitality, social functioning, emotional limitations on normal 
role activities (role emotional) and mental health. RLS patients had all of the SF-36 
scale scores significantly lower than the general population (2, 16, 19) see Figure 1. 
Despite the negative impact on QoL and effective treatment, RLS remains an under-
recognized and trivialized disorder. 
 
Figure 1: Comparison of mean Short Form 36 Health Survey (SF-36) scores of 
patients with restless legs syndrome with age- and sex-adjusted US population norms. 
Asterisks indicate that the scores of the RLS sufferer group were significantly below 
the norms for all 8 dimensions (2) 
The sleep loss in untreated RLS patients produces cognitive deficits involving pre-
frontal cognitive functions when compared to normal subjects. Similar changes have 
been described in patients with acute sleep deprivation, although RLS leads rather to 
chronic sleep deprivation (20).  
Affective disorders, including depression and anxiety are also very common in RLS 
patients. Recent studies have demonstrated higher prevalence of major depressive 
disorder and panic disorder in RLS. Depression affects up to 50% patients; those who 
suffer RLS have two to four fold higher risk of developing depression (21).  
Large epidemiological studies offer consistent and robust evidence for an association 
between RLS and cardiovascular disease. The underlying mechanism is complex. RLS 
may increase the risk for cardiovascular disorder and related conditions via action of 
the sympathetic nervous system and hypothalamic-pituitary-adrenal (HPA) axis.  
Periodic limb movements in patients with RLS are associated with arousals, as 
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manifest in the electroencephalogram, and all are followed by elevations in nocturnal 
blood pressure and puls rate. Increased nocturnal cortisol level and HPA axis 
dysregulation may be responsible for the relation of RLS to diabetes and impaired 
glucose tolerance (22, 23).  
 
Periodic limb movements in sleep (PLMS) 
Periodic limb movements in sleep (PLMs) represent a very frequent objective finding 
in RLS and contribute to sleep disruption (24). Up to 80 per cent patients with RLS 
experience PLMS (11, 25), they also may have periodic limb movements while awake 
(PLMW) (2).  
PLMS are best described as rhythmic extensions of the big toe and dorsiflexion of the 
ankle, PLMS are scored only if they are part of four or more consecutive movements 
lasting from 0.5 to 5 seconds with the inter-movement interval of 4 to 90 seconds. A 
PLMS index (number of PLMS per hour) greater than 5 is considered pathological 
(26). The number of PLMS varies from night to night. Roughly one third of PLMS are 
associated with arousals, as manifest in the electroencephalogram, leading to insomnia 
and increased cardiovascular risk in RLS patients. 
Quantification of PLMS is performed with polysomnography (Figure 2) and 
actigraphy (15), it has become accepted as an objective tool to evaluate the severity 
and treatment outcome in RLS patients (17). 
PLMS also occur in a wide range of disorders related to dopamine abnormalities such 
as narcolepsy, rapid eye movement behaviour (RBD) or Parkinson disease; they are 
often presented in sleep apnea syndrome, spinal cord lesions and are not specific to 
RLS. The PLMS are common in elderly patients without any sleep complaints. Some 
patients with otherwise unexplained insomnia or hypersomnia exhibited PLMS; this 
condition is defined as periodic limb movement disorder (PLMD). The clinical 





Figure 2: Polysomnogram of patients with RLS/PLMS. Duration of the hypnogram is 
2 minutes. From the top to bottom: hypnogram (blue), EEG (six black leads), ECG 
(purple), EOG (two black leads), EMG (two black leads) with periodic leg movements 
(arrows indicate a periodicity of 20 – 30s). 
 
 Epidemiology 
Prevalence rates of RLS, at least in Europe, identify this disorder as one of the most 
common neurological movement disorders. However, estimated prevalence in general 
populations does not overlap across studies even when the IRLSSG criteria are strictly 
applied. The subjective nature of the complaints, the fluctuating and variable course of 
symptoms, different populations and various methodological tools used such as 
questionnaires, telephone interviews, or direct face-to-face interviews may cause these 
discrepancies. Few studies in Western countries and Northern America have involved 
large population-based samples of subjects screened using the IRLSSG criteria. The 
RLS prevalence rate ranges from 7.2 to 11.5% in the general population (2, 16, 28).  
A minority of sufferers (around 3% of the population) experience daily or severe 
symptoms (2, 16). RLS is twice as common in women as in men (29). Parity or 
postmenopausal intake of oestrogen are to be considered as major factors in explaining 
this sex difference (29). 
 16 
RLS occurs in 3% of individuals from the Mediterranean or Middle Eastern region and 
in 1% of Asian population (30, 31), indicating that different genetic or environmental 
factors may play a role in the prevalence of this syndrome.  
Prevalence of RLS also increases with age. Increasing co-morbidity in the very old, 
however, may interfere with the accurate identification of RLS. 
Studies in children using diagnostic criteria for children established the prevalence rate 
in children to be 5.9% (32). 
 
RLS classification 
RLS can be divided into primary and secondary forms. Primary or idiopathic forms 
appear without apparent causes, they are not related to any medical conditions and 
include sporadic and inherited forms. Secondary forms occur in acquired forms 
associated with a variety of disorders. Iron deficiency, end-stage renal disease and 
pregnancy are thus well established secondary causes of RLS (5).  
 
Pathophysiology of RLS 
The pathophysiology of RLS is complex and remains unknown. RLS is predominantly 
a disorder of the central nervous system; dopamine and iron seem to play a 
fundamental role.  
The dopamine hypothesis derives from the dramatic improvement of RLS with 
dopaminergic therapy. The hypofunctioning of A11 dopaminergic diencephalon spinal 
pathways seems to be implicated in RLS ethiopathogenesis (33). The impaired iron 
homeostatis is another important pathophysiological issue, most patients have normal 
ferritin serum levels, but reduced levels in the cerebrospinal fluid (34). There is a 
substantial evidence for a genetic contribution to RLS, more then 60% of cases are 
familial. 
The different approaches used to define the pathophysiology of RLS are as follows:  
1) studies attempting to localize the areas of abnormal central nervous system 
(CNS) function (e.g. basal ganglia or spinal cord) 
2) studies of neurotransmitters 
3) studies of iron 
4) studies on the possible role of the peripheral nervous system in generating 
sensory symptoms in RLS 
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5) genetic studies 
CNS structures and areas which are involved in RLS 
pathophysiology 
There is a conflicting evidence for the cortical involvement in RLS pathophysiology. 
Electrophysiologic studies with transcranial magnetic stimulation have demonstrated 
an increased cortical excitability and decreased subcortical inhibiton, but normal motor 
threshold and conduction velocity suggest that the motor pathways are intact (35).  
The absence of corticospinal prepotentials on back-averaging, normal 
electroencephalogram, and the absence of high-amplitude cortical potentials in 
somatosensory evoked response argue against these movements being of cortical 
origin (36).  An altered cortical excitability may be the result of subcortical inputs, 
probably at the level of the basal ganglia. Therefore, dopaminergic modulation of 
intracortical excitability might play a key role in these dynamics (37). Some MRI 
studies have revealed the presence of morphologic changes in the somatosensory 
cortex, motor cortex and thalamic gray matter. Significant regional decreases of gray 
matter volume were found in the primary somatosensory cortex (38). However, this 
study conflicts with two others in which no cortical changes were found (39). A 
functional MRI study revealed abnormal bilateral cerebellar and thalamic activation 
during the manifestation of sensory symptoms, with additional red nucleus and 
reticular formation activity during PLMS (40).  
PLMS is likely to occur in patients with spinal cord lesions (41); several case reports 
described the onset of RLS in association with the spinal cord lesions (radiculopathy, 
traumatic lesion, etc.) (5). Sufficient evidence exists for hyperexcitability in motor and 
sensory spinal cord structures (42, 43).  It is unclear wether the hyperexcitability arises 
in the spinal cord itself or in the supraspinal areas (44). Patients with PLMS have 
significantly increased spinal cord excitability, as indicated by lower threshold and 
greater spatial spread of the spinal flexor reflex, which is more prominent during sleep 
(42).   Dopamine and opioids, two of the most effective therapies modulate spinal cord 
functions. L-DOPA depress flexors and nociceptive reflexes in the spinal cord (45). 
Opioids also play an important role in the control of sensory inputs to the spinal cord 
(see below). 
RLS symptoms seem to be the result of abnormal sensorimotor integration at the 
spinal cord level and abnormal central somatosensory processing. The 
hypofunctioning of the A 11 dopaminergic diencephalospinal pathway seems to be 
implicated in the RLS pathophysiology (33). A11 neurons are located close to sleep 
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related nuclei in hypothalamus  and  receive  diffuse projections from the 
suprachiasmatic nucleus, which largely  controls circadian rhythms (37).  A11 exists 
as the only source of dopaminergic innervation to the spinal cord (44, 46). This 
pathway is projecting from the hypothalamic area A 11 to D3 receptors located in the 
dorsal horns  and intermediolateralis spinal nuclei and it is crucial for sensorimotor 
integration and pain control at the spinal cord level (47). There is extensive evidence 
for the existence of D1, D2 and D3 receptors in the spinal cord, the study with  
D3receptor – knock-out mices (D3KO) suggest that D3 receptors are involved in the 
spinal cord excitability (48). This fact is in accordance with clinical studies in which 
RLS is best relieved by D3 receptor – preferring agonists. SCOR1 gene (see below) is 
selectively expressed in dorsal horns of the developing spinal cord, this fact may 
represent an interesting view on RLS pathophysiology. 
 
Studies of neurotransmitters 
Dopamine 
The strongest evidence for a dopaminergic role in RLS is an excellent response to 
dopaminergic medication (49) and worsening with dopamine release blockers.  Brain 
imaging studies of the dopaminergic system in the basal ganglia have not revealed 
consistent abnormalities. PET studies have shown little but significant reduction of 
mean caudate and putamen D2-receptor binding (50). Two SPECT studies did not find 
any difference in presynaptic DAT and striatal D2 receptor binding between RLS 
patients and controls suggesting normal pre-synaptic nigrostriatal terminal functions in 
RLS (51, 52), whereas one study (the only performed in the evening) reported a small 




The therapeutic effects of opioids were already noted by Ekbom and were examined in 
several clinical trials. Neurophysiological studies suggest that the pain system may be 
abnormal, patients with RLS exhibit profound static mechanical hyperalgesia to pin-
prick stimuli, but no dynamic mechanical hyperalgesia (allodynia). The hyperalgesia is 
reduced by long term dopaminergic treatment (43). Dopamine and opioids modulate 
the spinal cord functions, endogenous opioids may act upon dopamine systems to 
improve the symptoms of RLS (54). 
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Studies of iron 
The connection between RLS and system or CNS iron deficiency has long been 
recognized (34). Studies in idiopathic cases found normal serum iron values, but 
significantly reduced values in the cerebrospinal fluid compared to healthy controls. 
This indicates brain iron insufficiency and decreased availability of iron in the CNS in 
RLS patients (55). Magnetic resonance (MR) studies revealed decreased iron stores in 
substantia nigra and putamen in RLS patients; the decrease was most evident in 
patients with a severe form and early onset (12, 56), this was also confirmed in other 
studies using ultrasound methods. Overall, these studies suggest that general changes 
rather than local changes may account for clinical manifestations of RLS. There are 
several interactions between iron and dopamine (34). Iron is a cofactor for tyrosine-
hydroxylase, which is the rate-limiting step in the production of dopamine. Iron is a 
component of the dopamine type-2 (D2) receptor. 
Iron levels decrease at night (30 – 50%) leading to the dopamine decrease in the 
evening hours and to the typical circadian pattern of the disorder. 
Low serum ferritin levels are the best indicator of low iron store. Intravenous iron 
treatment showed successful, but transient improvement of RLS symptoms (57). 
 
The peripheral nervous system in generating sensory symptoms in 
RLS 
There is some evidence suggesting an association between RLS and peripheral 
neuropathy, but studies on this topic still remain controversial. Nerve conduction 
abnormalities and small-fibre neuropathy were found in a subset of RLS patients, 
especially in those with an older age of onset and negative familial history (58, 59). 
Other studies have failed to show this association; RLS was only 5.2% of 144 patients 
presenting with polyneuropathy, a prevalence not higher than that found in the general 
population (60). 
 
Genetics of RLS:  
Genetic factors participating in the RLS aetiopathogenesis has of late been repeatedly 
corroborated by several kinds of observations. About 40 – 60 % of idiopathic RLS 
patients report a positive family history; monozygotic twins are concordant for RLS in 
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80% (61). RLS is a highly familial phenotype with heredity estimates of about 50% 
(11), familial cases have a more slowly progressive course, the symptoms within a 
single RLS family can be variable. Based on the description of several large RLS 
families it is assumed that the disease follows an autosomal-dominant mode of 
inheritance. This was also confirmed by a segregation analysis in first degree family 
members. Findings in German and Czech populations suggest that heritability is 
higher in patients, who were younger than 30 at onset of symptoms (62).  
Linkage studies have revealed 8 loci so far, but no causally related gene variant has 
been identified yet. Recessive model of inheritance was identified on chromosome 12 
q in the family of French-Canadian origin. Further studies in families of Italian, 
American and German origin revealed loci on chromosome 14q (RLS 2), 9p (RLS3), 
20p (RLS4) and 2q (RLS5) with the dominant mode of inheritance. Other two loci 
were found in one family on chromosome 4q a 17q, a suggestive locus is also on 
chromosome 19 (63). 
So far, all of these linkage analyses of RLS families have met limited success and have 
not led to the identification of the disease-causing mutation. This fact provides indirect 
evidence for the complexity of RLS. 
Apart from the linkage loci, which represent genetic variants of stronger effect, but are 
usually rare, association cases control studies are able to detect variants of smaller 
effect, which are more common in patients suffering from RLS.  Association studies 
compare the frequencies of alleles in case and control populations. A higher frequency 
of the allele tested in cases is taken as evidence that the allele or genotype is associated 
with an increased risk for the disease. A genome-wide association study (GWAS) with 
German and Canadian RLS idiopathic cases revealed association with three gene 
variants in MEIS1 on chromosome 2, BTBD9 on chromosome 6 and in region between 
MAP2K5 and SCOR1 on chromosome 15q (64). A replication study from the USA 
confirmed the association of MEIS1 and BTBD9, however the MAP2K5/SCOR1 locus 
showed only a trend for association (65). Another GWAS conducted in US and 
Iceland population showed association of BTBD 9 variants with periodic limb 
movements in sleep (PLMS) (66). The fourth loci, PTPRD on chromosome 9 was 
identified in the European and Canadian population (67). An association was 
identified with intronic variants, which suggests a functional role in the expression or 
alternative splicing of the gene. Carriers of one risk allele had a 50% increased risk for 
developing RLS. A closer inspection of the known function of the genes is surprising 
because some of them are developmental factors and did change the 
pathophysiological concept of RLS. The most recent GWAS including European 
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samples revealed new association loci, the first on chromosome 2 is an intergenic 
variant outside of MEIS1 region and the second on chromosome 16 containing the 5'-
end of TOX3 (68). 
MEIS1 (myeloid ecotropic viral integration site homeobox 1) is a member from a 
highly conserved family of TALE homeobox genes. MEIS1 plays a role in 
proximodistal limb formation during embryonic development, it is also part of a HOX 
transcriptional regulatory network that specifies spinal motor neuron pool identity and 
connectivity (69). The specific function in postembryonic tissue remains to be 
established, MEIS1 is expressed in the adult mouse brain in cerebellar granule cells, 
the forebrain and, notably, in dopaminergic neurons of substantia nigra. MEIS1 has 
been found to be overexpressed in acute myeloid leukemia (64). 
 
Figure 3: MEIS 1gene 
The second region with significant association was found on chromosome 6p in intron 
of the BTBD9 gene. BTBD9 (BTB/POZ domain-containing protein 9) gene appears to 
be expressed in the periphery and in the central nervous system. The function of BTB 
(POZ) proteins includes transcription repression, cytoskeleton regulation, gating of ion 
channels and ubiquitin-dependent protein degradation (64). The specific function is 
not known due to universal occurrence. Interestingly, the association of BTBD9 was 
found in subjects who had PLMS without RLS but not in subjects with RLS without 
PLMS. Furthermore, an analysis of parameters involving iron metabolism revealed 
that the risk allele was also associated with a 13% decrease of the serum ferritin levels 
(66).  
The third region on 15p chromosome contains MAP2K5, a member of the mitogen 
activated protein kinase family, and the adjacent SCOR1 gene (64). MAPK pathways 
are activated by a signaling cascade that mediate the transduction of extracellular 
signals to cytoplasmic nuclear effectors; this pathway is important in neuroprotection 
of dopaminergic neurons. MAP kinase cascade is critical at early stages of muscle cell 
differentiation. SCOR1 acts as a corepressor of LBX1, this homeobox gene is critical in 
the development of sensory pathways in the dorsal horn of the spinal cord (70). 
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PTPRD (protein tyrosine phosphatase receptor type delta) belongs to the family of 
type IIa receptor-like protein tyrosine phosphatase; the involvement of PTPRD in RLS 
is unknown. Studies in PTPRD knockout mice have shown that these proteins function 
in axon guidance and termination of mammalian motoneurons during embryonic 
development (67, 71).   
TOX3 is a member of the high mobility box group family of non-histone chromatin 
proteins which interacts with CREB and CBP and plays a critical role in mediating 
calcium-dependent transcription in neurons (68). 
The identification of genetic variants has been a large step forward in unraveling the 
genetics of RLS. We still do not know whether RLS has components of a 
developmental disorder and whether the genes identified play a role in early 
embryonic days or have a completely different function in the elderly. None of these 
genes is related to dopamine or dopamine receptors, the genetic background of 
dopaminergic response remains to be solved. 
It is now necessary to investigate relations between genetic and environmental factors 
such as iron deficiency, pregnancy, renal failure, etc. Secondary RLS cases may 
present genetically susceptible individuals with a clearly defined provoking factor 
(63). The only study, which demonstrated the influence of genetic factors in secondary 
RLS, was performed in patients with an end stage renal disease. Schormair et al. 
investigated the known genetic variants (MEIS1, BTBD9, MAP2K5/SCOR1, PTPRD) 
in a case-control association study of uremic patients from Germany and Greece. RLS 
in patients with an end stage renal disease was associated with MEIS1 and BTBD9 in 
the German sample, whereas, in the Greek sample, there was a trend for association 
for BTBD9 and MAP2K5/SCOR1 (72). 
 
Secondary RLS:  
Secondary RLS are related to other medical or neurological conditions. Well-
documented associations include renal failure, iron deficiency and pregnancy. In fact, 
at least 20 disorders have been reported in the literature. Some of these are likely 
chance occurrences owing to the past underestimated prevalence of RLS. The 
diagnostic criteria for primary and secondary forms are identical (4-6). Although not 
yet formally studied, the secondary forms of RLS probably share the same clinical 
features as idiopathic RLS, suggesting a similar underlying pathophysiological basis, 
including the genetic factors (63).   
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RLS is associated with several neurological disorders such as spinal cord lesions 
(myelopathy, traumatic lesions, spinal anesthesia, etc.), genetic ataxias (SCA 1 – 3), 
Parkinson’s disease, essential tremor and probably with neuropathy. RLS can be 
triggered by medication (e.g. SSRI) (6).  
The prevalence of RLS in uremic patients ranges from 20% to 57% (73), RLS 
symptoms are usually very severe and RLS is associated with increased mortality. 
Kidney transplantation leads to dramatic improvement of RLS. Anemia, neuropathy 
and genetic factors (see above) may cause this secondary RLS form.  
Pregnant women have 2–3 higher risk of developing RLS than the general population, 
the prevalence in pregnancy is estimated at 10–27%. Symptoms usually appear or get 
worse in the last trimester and RLS is resolved after the delivery in vast majority. 
Three factors are speculated in aethiology: 1) impaired metabolism of iron and folate, 
2) hormonal changes (progesterone increases the excitability of the nervous system) 
and 3) psychosomatic factors (74). 
All conditions which lead to system iron deficiency may cause RLS. RLS is common 
in anemic patients and regular blood donation may lead to iron deficiency (75).  
Restless legs syndrome in patients with multiple sclerosis 
The recent studies showed a higher prevalence of RLS in patients with multiple 
sclerosis, which ranges from 19% to 37.5%. Three major epidemiological 
investigations have been published so far. Auger et al. performed the first issue on this 
topic in the French-Canadian population, finding a very high prevalence in both 
patients and controls (37.5% vs. 16%), only a self-administered questionnaire without 
a personal interview was used (76). This methodology may overestimate the 
prevalence of RLS due to false positive cases; other two studies used a face to face 
interview. The second study, published by Spanish authors, showed different results – 
a similar prevalence rate of RLS in MS patients and in healthy subjects (13.3 % vs. 
9.3%), but they did not use clear exclusion criteria for patients and subjects and the 
sample of patients was small (77). The largest study, published by an Italian group, 
showed a prevalence of 19% in MS and 4.2% in control subjects (78). They chose the 
frequency of symptoms occurrence at least twice a week as a threshold for the 
diagnosis of RLS. They did not include patients who experienced the symptoms with a 
frequency of occurrence lower than twice per week (further 7.3%, total RLS 
prevalence 26.3%). Figure 4 shows the strong dependency of RLS prevalence rate, in 
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both controls and cases groups, on the frequency of RLS symptom occurrence chosen 
as a threshold for the diagnosis of RLS. Different methodology, frequency criteria and 
population might explain discrepancies in absolute values in the estimation of 
prevalence rates among these studies.  
 
Figure 4: Likelihood of prevalence rate of restless legs syndrome (RLS), in both 
control subjects and patients with RLS, based on the frequency of RLS symptom 
occurrence chosen as a threshold for the diagnosis of RLS (78). 
 
Among patients with MS, RLS is associated with older age, longer MS duration and 
more severe neurological disability specifically involving the pyramidal and the 
sensitive EDSS (Expanded disability status scale) functional systems (Figure 5). 
Patients with MS and RLS reported poorer sleep quality and higher intake of drugs 
(hypnotics, baclofen and antidepressants). RLS was more prevalent in the primary-
progressive form when compared with relapse-remitting form (Figure 6). Thus RLS 
was associated with a higher MS disability and with the most severe MS course. The 
RLS clinical onset in the majority of MS patients followed MS onset, at least a small 
portion of patients (4%) may be idiopathic (RLS preceded MS). The severity of RLS 
symptoms was higher in patients with MS than in control subjects (78).  
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Figure 5: Comparison of Expanded Disability Status Scale (EDSS) scores found in 
MS/RLS+ and MS/RLS– patients. MS refers to multiple sclerosis; RLS to restless legs 
syndrome *mean ± SD (78) 
 
 
Figure 6: Distribution of the frequency of the 3 clinical courses of multiple sclerosis 
(MS) in patients with and without RLS. RR refers to relapsing remitting; SP to 
secondary progressive; PP to primary progressive (78). 
 
The pathophysiology of this association remains to be investigated. Research on 
secondary forms may help in understanding which central nervous structure is 
responsible for RLS. 
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Manconi et al. compared the extent of brain and cervical cord damage in MS patients 
with and without RLS using conventional and diffusion tensor magnetic resonance 
imaging (MRI). Global and regional dual-echo lesion load (LL), number of cervical 
cord lesions, mean diffusivity (MD) and fractional anisotropy (FA) histograms of the 
brain and cervical cord were assessed. No difference between the two groups was 
found in the whole brain, cerebellar and brainstem lesion load, MD and number of 
cervical lesions. Cervical cord average FA was significantly reduced in MS patients 
with RLS compared to those without, pointing out that the cervical cord damage 
represents a significant risk factor for RLS in MS patients (79).  
Conventional MR technique provides a crucial step for the diagnosis in MS. However, 
the gold diagnostic and prognostic standard, T2-weighted MRI has shown only a 
limited association with the disability progression due to the limited ability to 
characterize and quantify the heterogenous MS pathology ( i.e. demyelination, axonal 
loss and gliosis)(80). The correlations between the conventional T2 lesion load and 
clinical outcome are strong in patients seen at the first presentation with clinically 
isolated syndromes suggestive of MS, but much weaker in established MS (81). Thus, 
more specific MR parameters and techniques (MR spectroscopy, functional MRI) have 
been developed to monitor disease progression and treatment efficacy. MRI volume 
parameters include brain atrophy and brain parenchymal fraction (82). Serial MRI 
studies have demonstrated that brain volume loss occurs at a rate around 0.5 – 0.1% 
per year in MS patients compared with a rate of about 0.1 – 0.3% per year in age 
matched healthy subjects (80). Brain atrophy begins early in the disease course and 
both global brain and selective grey matter measures of volume loss have been closely 
associated with the disease progression. Brain parenchymal fraction represents another 
approach to measure brain atrophy, it is defined as the ratio of brain parenchymal 








AIM OF OUR STUDY 
The aim of our study was to further investigate the pathophysiology of primary and 
secondary forms of restless legs syndrome focusing on clinical and genetic aspects of 
this disorder, mainly in patients with multiple sclerosis. Our study is divided in a 
genetic and clinical part. 
Clinical study:  
The aim of the epidemiological and radiological study was to evaluate the prevalence 
of RLS among Czech patients with multiple sclerosis, to further analyze risk factors 
for developing RLS in patients with MS and to compare the extent of brain damage 
between MS patients with and without RLS using magnetic resonance imaging (MRI). 
Hypothesis: MS is a new secondary RLS form, RLS is a common finding also among 
Czech patients with MS, the presence of RLS correlates with the clinical progression 
of MS and with the extent of brain damage on brain MRI. 
 
Genetic study:  
1) The aim of the study “Replication in three populations” in idiopathic RLS was 
to evaluate whether common genetic variants (MEIS1, BTBD9 and 
MAP2K5/SCOR1) are also relevant among other Europeans (Czech, Austrian, 
and Finnish) and what is the difference of their impact between sporadic and 
familial cases.  
Hypothesis: Common genetic variants also increase the risk for the idiopathic RLS 
form in other populations. 
2) The aim of the study “Genetics of secondary RLS form in patients with 
multiple sclerosis” was to investigate whether the common genetic variants 
(MEIS1, BTBD9, MAP2K5/SCOR1 and PTPRD)  have also an impact on RLS 
in patients with multiple sclerosis. 
Hypothesis: Secondary and primary RLS share at least some common genetic factors. 
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PATIENTS AND METHODS 
Clinical study 
Epidemiological and radiological study – prevalence of RLS in 
patients with multiple sclerosis and brain magnetic resonance 
imaging study in patients with RLS and MS 
 
Patients 
From April to December 2009, we recruited all patients with multiple sclerosis from 
the preselected population (patients with quantitative MRI data) in the MS Centre, 
Department of Neurology of First Faculty of Medicine, Prague. MS had been 
diagnosed according to McDonald criteria (84). Exclusion criteria for the study were 
dopaminergic and antidopaminergic drugs, renal failure, pregnancy, sideropenic 
anaemia, another disease known to be related to RLS, recent MS diagnosis (less than 6 
months before the time of the interview) and recent clinical MS relapse (within 3 
months of the interview). No specific limitations were used regarding chronic MS 
treatments with disease-modifying drugs. On the basis of its clinical course, MS was 
classified as primary progressive, secondary progressive or relapsing remitting. Each 
MS patient underwent a semi-structured interview and brain magnetic resonance 
imaging (MRI). An interview was conducted by a physician skilled in RLS 
diagnostics. A patient was considered to be affected by RLS if all four standard criteria 
had ever been met in his/her lifetime (2).  
Magnetic resonance imaging (MRI) data for each patient were obtained during the 
year before the interview, MR analysis was performed by an experienced observer, 
who was unaware of the identity of scans.  
 All MRI scans were performed with Philips Gyroscan NT 1.5 T (Philips Medical 
Systems, Best, the Netherlands; software update in 2001, hardware update in 2004). 
Axial brain images were acquired using fast fluid-attenuated inversion recovery 
(FLAIR) and T1-weighted three-dimensional fast field echo images, we used our in-
house developed software (ScanView 1.0.7). Image analysis was performed as 
described elsewhere (85). Three volumetric parameters (absolute values and changes 
against baseline) were measured: brain atrophy (Picture 1 – 3), brain parenchymal 
fraction (BPF) and T2 lesion load (T2LL) (Picture 4). T1-weighted images were used 
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to assess brain atrophy, and brain tissue was outlined semi-automatically. BPF was 
calculated as the ratio of the brain tissue volume to the total volume contained within 
the brain surface contour (83). T2 lesion load was identified on FlAIR scans.  
 
 
Picture 1: Brain atrophy in 31-year-old patient with MS (FLAIR) 
                              




Picture 3: Brain atrophy – technique of measurement 
 
Picture 4: Lesion load (FLAIR) 
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Statistical analysis:  
The data were analyzed using the software package Statistica 8 (StatSoft, Inc. 
STATISTICA for Windows, Tulsa, OK: 2300 East 14th Street, Tulsa, OK 74104, 
http://www.statsoft.com). Results are presented as mean ± one standard deviation; 
nonparametric descriptive statistics and an inter-group comparative test (Mann-
Whitney) were used to analyze EDSS scores. T-tests were employed for all other 
parameters. 
 
Genetic study  
1) Replication in three populations:  
Patients and Controls  
The diagnosis of all RLS cases was made according to the diagnostic criteria of the 
International RLS Study Group by personal examination by a neurologist in the 
respective study center. Positive family history was defined as at least one first-degree 
family member being affected by RLS (reported by the proband) in all three 
populations. The control samples originate from the general population and were not 
screened for presence of RLS. 
Czech subjects – The patients were recruited in the center for Disorders of Sleep and 
Wakefulness, Department of Neurology of First Faculty of Medicine and the General 
Teaching Hospital, Prague. In total, 290 patients were included (107 males, mean age 
55.7  15.3 years (  SD), mean age at onset of RLS 38.3  18.1 years). Positive family 
history was reported by 110 patients, in 175 cases it was negative and in five the data 
were not available. Altogether 450 sex matched controls were selected randomly from 
the Czech blood and bone marrow donors registry (166 males, mean age 45.3  9.9). 
Since the maximum age for the controls was 63 years, 38 male and 51 female cases in 
the age group from 64 to 91 years could not be age matched.  
Austrian subjects – 269 (104 males) patients were recruited in 2 centers: at the 
Department of Neurology, Medical University of Vienna and the Department of 
Neurology, University Clinic Innsbruck, (mean age 59.0  14.3, mean age at onset of 
RLS 37.14  19.5). Positive family history was reported by 107 patients, in 108 cases 
it was negative and in 54 the data were not available. The patients were matched by 
sex to 611 controls from the German KORA project, whose procedures were described 
elsewhere (86) (236 males, mean age 59.9  11.35). KORA controls were already used 
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in the previous GWA study, which showed only negligible effect of population 
stratification (64). 
Finnish subjects – 90 (24 males) patients were recruited in the Sleep Research Center 
in Turku (mean age 46.5  18.1, mean age at onset of RLS 19.4  13.4). Positive 
family history was reported by 81 patients and 9 patients had a negative family history. 
A random sample from the general Finnish population, comprising 169 sex matched 
individuals (45 males) was used as control. Data on age of controls were not available. 
Studies were performed according to the declaration of Helsinki and approved by the 
Ethical Committee of the respective study centers. Written informed consent was 
obtained from all RLS patients.  
 
Genotyping 
Ten SNPs within the three genomic regions were selected according to the results of 
previous GWA scans (64, 66). Samples were genotyped on two Sequenom platforms 
in Munich and Helsinki (Sequenom MassArray system, Sequenom Inc, San Diego, 
CA, USA) with a genotype discordance rate of 1.3% in 158 comparisons, when 
analyzing repeatedly genotyped internal control samples. Automated genotype calling 
was done with SpectroTYPER 3.4 software and genotype clustering was visually 
checked by an experienced scientist. Assays were designed using AssayDesign 3.1.2.2 
with iPLEX Gold chemistry default parameters. SNP quality control criteria leading to 
exclusion from analysis were a call rate < 90%, MAF < 1% and P < 0.001 for 
deviations from HWE in controls.  
 
Statistical analysis 
Genotype data were analyzed using standard association tests (allelic, genotypic, 
dominant and recessive models) including Cochran-Armitage test for trend, Cochran-
Mantel-Haenszel test for estimation of ORs in the stratified sample (including 
Breslow-Day test for homogeneity) and haplotype tests, as implemented in the PLINK 
statistical package v1.0.v (87). The sample was stratified only according to the country 
of origin. Logistic regression implementing the Cochran-Armitage test for trend (using 
genotypes as ordinal values rather than categorical) in the combined sample using age, 
sex and country of origin as covariates was performed by generalized linear modeling 
routines incorporated in R package v.2.6.0 (http://www.r-project.org/). Bonferroni 
correction for multiple testing of ten markers was employed. All P-values given are 
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one-sided, with the direction of the alternative hypothesis given by the original report 
(66). Power calculations were performed using the Genetic Power Calculator 
(http://pngu.mgh.harvard.edu/~purcell/gpc/) (87). For input parameter we used a RLS 
prevalence of 8%, an alpha-level of 0.05% and ORs and allele frequencies according 
to results from the GWA experiment (64). Association tests were conducted in three 
different settings: 1. All patients (i.e. familial and sporadic) combined versus all 
controls, 2. familial cases versus controls, and 3. sporadic cases versus controls.  
 
2) Genetics of secondary RLS form in patients with multiple 
sclerosis 
Patients 
Participants in the epidemiological study (see above) were asked to take part also in 
the genetic association study. We also recruited more patients with clear cut secondary 
RLS to increase statistical power and did not use all the RLS negative patients so as 
not to exceed the 2:1 ratio between controls and cases. As a reference population, 
blood donors were used – the same sample as described in the previous study (p. 39). 
The genetic association study included 642 subjects; 203 MS patients (45 men, 158 
women, mean age 40.7 years, SD ±10.7) with RLS were compared to 438 MS patients 
(122 men, 316 women, mean age 35.8 years, SD ±9.3) without RLS and to a reference 
population of 450 blood donors (166 males, 284 females, mean age 45.3 9.9). 
We excluded patients who had experienced RLS prior to the first symptoms of MS and 
patients with a positive family history of RLS to minimize the admixture of idiopathic 
cases.  
Association tests were conducted in different settings: 1) patients with MS with RLS 
combined versus patients with MS without RLS 2) patients with MS with and without 
RLS versus population controls (blood donors not screened for RLS) and Czech 
sample of idiopathic RLS (see above).  
The Local Ethics Committee approved the study and written informed consent was 
obtained from all subjects.  
Twelve single nucleotide polymorphisms (SNPs) within the four genomic regions 
were selected according to the results of previous GWA scans (64, 67). Samples were 
genotyped on Sequenom platform (Sequenom MassArray system, Sequenom Inc, San 
Diego, California, USA). Automated genotype calling was done with SpectroTYPER 
3.4 software and genotype clustering was visually checked by an experienced scientist. 
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Assays were designed using AssayDesign 3.1.2.2 with iPLEX Gold chemistry default 
parameters. SNP quality control criteria leading to exclusion from analysis were a call 
rate, 90%, minor allele frequencies (MAF), 1% and p=0.001 for deviations from 
Hardy-Weinberg equilibrium (HWE) in controls.  
 
Statistical analysis:  
Genotype data were analyzed using standard association tests (allelic, genotypic, 
dominant and recessive models) including the Cochran-Armitage test for trend and test 
for empirical significance as these are implemented in the PLINK statistical package 
v1.0.11. (87). 
Bonferroni correction for multiple testing of 4 regions (all genotyped SNPs within 
each region are in close linkage disequilibrium, except for chromosome 9) and 2 
different models (allelic and the best model) were employed. All p values given are 
two-sided. 
Power calculations were performed using the Genetic Power Calculator 
(http://pngu.mgh.harvard.edu/~purcell/gpc/) (88). For input parameter we used an RLS 
prevalence of 8%, an alpha level of 5%, and ORs and the allele frequencies according 





Epidemiological and radiological study – prevalence of RLS in 
patients with multiple sclerosis and brain magnetic resonance 
imaging study in patients with RLS and MS 
 
In total, we enrolled 765 MS patients (553 females and 212 males). The mean age was 
36.5 ±9.5 years with average disease duration of 9.1 ±7.36 years. The median EDSS 
score was 2.0 (quartiles 1.5 and 3.5).  
Out of all the examined patients, 76% had relapse-remitting MS, 14.4% had clinically 
isolated syndrome, 5.6% were in secondary progression and 0.9% had a primary 
progressive form of MS. 
The diagnosis of RLS was confirmed in 245 subjects (32%, 95% CI 28.7–35.4%) with 
MS, mean age at onset of RLS symptoms was 29.1 ±10.4 years. In 49 patients (6.4%), 
RLS symptoms preceded the MS onset and 19 patients (2.4%) had a positive family 
history and RLS symptoms preceding the MS onset, and therefore were subsequently 
excluded from all genetic studies (Graph 1). In 177 patients (23.2%) RLS followed the 
MS onset, 520 patients (68%) never experienced RLS. The average delay between the 
onset of MS and that of RLS was 2.5 ±8.7 years. 
For individual subtypes of MS, using the same strict criteria (exclusion of patients 
with positive family history of RLS and onset of RLS symptoms before MS) we 
observed the following RLS prevalence: In relapse-remitting MS 39.6% (95% CI 
35.36% to 43.84%), in clinically isolated syndrome 21.7% (95% CI 12.83% to 
30.57%) and in secondary progressive MS 61.5% (95% CI 46.23% to 76.77%) (Graph 
2). 
Compared to patients without RLS, patients suffering from both MS and RLS were 
significantly older (38.6 vs. 35.6 years, p<0.001, Students t-test), had longer durations 
of MS symptoms (11.0 vs. 8.2 years, p<0.001, Student’s t-test) and had higher EDSS 
scores (2.9 vs. 2.3, p<0.001, Mann-Whitney test) (Graph 3–5). There were 







































Graph 2: Prevalence of RLS in different clinical courses of MS, CIS – cilinical 































































Graphs 3–5: Risk factors for developing RLS in MS patients 
 
Quantitative MRI data were obtained in 385 patients without RLS (mean age 38.3 ± 
10.2 years, mean MS duration 12.0 ± 6.3 years, median EDSS score 2.6 ± 1.5) and 215 
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patients with RLS (mean age 41.4 ± 10.4 years, mean MS duration 14.5 ± 7.6 years, 
mean EDSS 3.2 ± 1.4). 
We found no difference between the two groups in the whole brain lesion load, brain 
atrophy and brain parenchymal fraction (Table 1), despite the fact that we were able to 
replicate the correlation of these data with clinical parameters of MS (Table 2). 
  
Table 1: Quantitative brain MRI data from MS-patients) without RLS (MS/RLS-
) and with RLS (MS/RLS+) 
 MS/RLS- MS/RLS+ t-value p-value 
Age 38.318 41.426 -3.67371 0.00026 
Lesion load – T2 6.555 6.579 -0.03019 0.975928 
Brain parenchymal fraction 84.495 84.5 -0.02666 0.978737 
Atrophy – T1 % 98.44 98.436 0.02306 0.981608 
 
Table 2: Correlation of MRI data with clinical parameters of MS 







0.2786 -0.3131 0.1991 
p=.000 p=.000 P=.007 
Age at RLS onset 
0.1083 -0.1815 0.0758 
p=.144 p=.014 P=.308 
MS duration 
0.406 -0.3517 0.0851 
p=.000 p=.000 P=.252 
EDSS 
0.4331 -0.4308 0.0141 




 Genetic study  
1) Replication in three populations:  
 
All SNPs (Table 4) tested were in HWE (p > 0.01) in both patients and controls. Under 
assumption of genetic homogeneity, the combined sample had good power to detect 
association using previously published parameters (64) (98% for MEIS1 and BTBD9, 
89% for MAP2K5/SCOR1). In the Czech sample alone the power was 82.5% for 
MEIS1 and BTBD9, 71.8% for MAP2K5/SCOR1; in the Austrian sample, the powers 
were 84.8% and 74.8%, respectively; and in the Finish sample separately 38.7% and 
30.4%. 
Allele frequencies in the Czech and KORA control samples were not significantly 
different (lowest P in 
2 
test = 0.2045 for rs4236060). Significant allele frequency 
differences were observed between the Finnish and the combined Czech and KORA 
control samples within BTBD9 (P < 7.67x10
-6
 for all SNP markers within BTBD9). A 
similar, nominally significant, difference in allele frequencies in BTBD9 markers was 
also observed between Finnish cases and combined Czech and Austrian cases (in 
2 
test lowest P = 0.01063 for rs9296249), but we did not observe a significant difference 
between allele frequencies of Czech and Austrian RLS patients (lowest P in 
2 
test was 
0.4608 for rs2300478). Logistic regression showed no significant interaction with 
country for any SNP tested, and Breslow-Day test showed homogeneous ORs in all 
samples (Table 5). 
Significant association after correction for multiple testing at significance level alpha = 
5 % was found in at least one SNP for all tested loci in the combined samples (Table 
3), and in the Czech and Austrian samples separately. Analyzing the Finnish sample, 
we confirmed only the association to BTBD9. The association to rs2300478 in MEIS1 
was only nominally significant and MAP2K5/SCOR1 showed no association (Table 4). 
In the combined sample we observed a strong association with the haplotype formed 
by markers rs6710341 and rs12469063, both located within MEIS1. Carriers of the 
“AG” haplotype had ORs for developing RLS of 1.98 (P = 9.1x10
-10
). Results for this 
haplotype were similar when testing the Czech (P = 3.2 10
-7
, OR = 2.38), Austrian (P 
= 8.3x10
-5
, OR = 1.82), and Finnish samples (P = 2.0x10
-4
, OR = 2.46) separately. No 
other common polymorphic phased haplotypes (MHF > 1%) yielded significant 
results. An allele dosage model best described the association for MEIS1 and BTBD9 
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(Armitage trend test). In contrast, a recessive model for the risk allele fitted best for 
the MAP2K5/SCOR1 locus (Table 6).  
Analyzing only familial cases (n = 217) and all controls, all three loci were 
significantly associated. Using sporadic cases only (n = 283), we would confirm the 
association to BTBD9 but not to MEIS1 and MAP2K5/SCOR1. We omitted patients of 
Finnish origin from this sub-analysis due to very low proportion of sporadic cases and 
different allele frequencies in these samples. The Breslow-Day test did not show 
significant heterogeneity between sporadic and familial cases. 
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Table 3: Genotyped SNPs and Results of Association in Combined Samples 
The Genetic positions in bp and gene alignments are derived from UCSC Genome browser (http://genome.ucsc.edu, assembly March 2006) (89) r
2
 – linkage 
disequilibrium relative to preceding marker, data were computed using genotypes observed in both cases and controls using Haploview 4.0 from HapMap 
project (http://www.hapmap.org, release 21a) (90) OR – Odds ratio for the risk allele (Cochran-Mantel-Haenszel test) with 95% confidence intervals, P nom – 
Logistic regression implementing Armitage trend test with country of origin, sex and age as covariates, P corr – adjusted P values for multiple testing, MAF – 
minor allele frequencies observed in combined Czech and Austrian sample, in sporadic and familial cases, Best model corresponds to model, under which 
lowest P values were observed (TREND – Armitage trend test, REC – recessive model), P corr Fam. – comparison of allele frequencies between familial cases 
and all controls, P corr Spor – comparison of allele frequencies between sporadic cases and all controls. † risk allele is the major allele.  
Chr Gene SNP ID Genome r
2
 OR 
(95% Conf. Int) 










2p MEIS1 rs6710341 66611926  0.84 (0.64-1.11) 0.30646 1 0.1270 0.1288 TREND 1 1 
2p MEIS1 rs12469063 66617812 0.413 1.43 (1.16-1.78) 4.15E-06 4.15E-05 0.3522 0.2727 TREND 2.24E-05 0.3245 
2p MEIS1 rs2300478 66634956 0.969 1.47 (1.18-1.82) 1.26E-06 1.26E-05 0.3575 0.2860 TREND 3.10E-05 0.1520 
6p BTBD9 rs9296249 38473818  1.59 (1.26-2.01) † 0.00011 0.00107 0.1694 0.1553 TREND 0.0544 0.0012 
6p BTBD9 rs3923809 38548947 0.512 1.58 (1.28-1.96) † 4.11E-06 4.11E-05 0.2204 0.2330 TREND 0.0018 0.0022 
6p BTBD9 rs4236060 38578315 0.829 1.49 (1.19-1.86) † 1.93E-05 0.00019 0.1882 0.2110 TREND 0.0008 0.0049 
15q MAP2K5 rs11635424 65824631  1.26 (1.02-1.55) † 0.00602 0.06023 0.2446 0.2992 REC 0.0203 1 
15q MAP2K5 rs3784709 65859328 0.935 1.24 (1.01-1.52) † 0.00530 0.05301 0.2392 0.2917 REC 0.0393 1 
15q MAP2K5 rs1026732 65882138 0.966 1.27 (1.03-1.56) † 0.00428 0.04278 0.2339 0.2936 REC 0.0116 1 
15q MAP2K5/ 
LBXCOR1 
rs6494696 65890259 0.999 1.27 (1.03-1.56) † 0.00476 0.04764 0.2339 0.2936 REC 0.0108 1 
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Table 4: Analysis in individual populations 
MAF – minor allele frequencies in each subsample in patients and healthy individuals, N – numbers of successfully genotyped individuals bypassing quality 
control criteria, Best P corr – P values corrected for multiple testing according to the full association model in Table 1, OR - Odds ratio and corresponding 
95% confidence intervals. 
 
 Czech Republic Austria Finland 






























(95% Conf. Int) 
rs6710341 0.1309 0.1456 1 1.13 (1.55-0.83) 0.1306 0.1412 1 0.91 (0.66-1.26) 0.1207 0.1585 1 0.73 (0.43-1.22) 
rs12469063 0.2971 0.2172 0.0492 1.52 (1.19-1.95) 0.3108 0.2426 0.0064 1.41 (1.11-1.79) 0.3161 0.2439 0.6093 1.43 (0.98-2.10) 
rs2300478 0.3025 0.2209 0.0285 1.53 (1.20-1.96) 0.3243 0.2487 0.0017 1.45 (1.14-1.84) 0.3276 0.2459 0.3676 1.49 (1.02-2.18) 
rs9296249 0.1649 0.2306 0.0252 1.52 (1.15-2.00) 0.1644 0.2378 0.0116 1.59 (1.19-2.11) 0.2414 0.3516 0.1081 1.70 (1.15-2.53) 
rs3923809 0.2301 0.2998 0.0374 1.43 (1.12-1.84) 0.223 0.3133 0.0049 1.59 (1.23-2.05) 0.2651 0.4119 0.0124 1.94 (1.32-2.87) 
rs4236060 0.2047 0.2662 0.1903 1.41 (1.09-1.83) 0.1968 0.2891 0.0028 1.66 (1.27-2.17) 0.2674 0.3921 0.0497 1.77 (1.20-2.60) 
rs11635424 0.2772 0.3350 0.0135 1.31 (1.04-1.66) 0.2793 0.3229 0.1014 1.23 (0.97-1.57) 0.3046 0.2866 1 1.09 (0.75-1.59) 
rs3784709 0.2754 0.3289 0.0124 1.29 (1.02-1.63) 0.2725 0.3185 0.0522 1.25 (0.98-1.59) 0.3046 0.2744 1 1.16 (0.79-1.69) 
rs1026732 0.2717 0.3350 0.0050 1.35 (1.07-1.71) 0.2748 0.322 0.0519 1.25 (0.98-1.60) 0.3046 0.2764 1 1.15 (0.79-1.67) 
rs6494696 0.2717 0.3350 0.0050 1.35 (1.07-1.71) 0.2748 0.3229 0.0416 1.26 (0.99-1.60) 0.3046 0.2764 1 1.15 (0.79-1.67) 
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Table 5: Results of Cochran-Mantel-Haenszel test in all 3 populations 
TEST – TOTAL represents all sources of variance, ASSOC association without assuming 
heterogeneity, HOMOG test for homogeneity, 1 Czech samples, 2 Austrian samples and 3 
Finish samples. CHISQ – the actual value of chi-square statistic. DF – number of degrees of 
freedom, P – nominal P values. OR – Odds ratio.  
 
CHR SNP ID TEST CHISQ DF P OR 
2 rs6710341 TOTAL 1.9040 3 0.5926 NA 
2 rs6710341 ASSOC 1.5190 1 0.2178 NA 
2 rs6710341 HOMOG 0.3851 2 0.8248 NA 
2 rs6710341 1 0.5741 1 0.4486 0.8858 
2 rs6710341 2 0.2722 1 0.6018 0.9180 
2 rs6710341 3 1.0580 1 0.3038 0.7537 
2 rs12469063 TOTAL 21.5900 3 0.0001 NA 
2 rs12469063 ASSOC 21.3600 1 0.0000 NA 
2 rs12469063 HOMOG 0.2341 2 0.8895 NA 
2 rs12469063 1 11.2100 1 0.0008 1.5230 
2 rs12469063 2 7.7250 1 0.0054 1.4090 
2 rs12469063 3 2.6610 1 0.1028 1.3990 
2 rs2300478 TOTAL 24.1900 3 0.0000 NA 
2 rs2300478 ASSOC 24.0900 1 0.0000 NA 
2 rs2300478 HOMOG 0.1051 2 0.9488 NA 
2 rs2300478 1 11.5800 1 0.0007 1.5300 
2 rs2300478 2 9.2940 1 0.0023 1.4510 
2 rs2300478 3 3.3170 1 0.0686 1.4510 
6 rs9296249 TOTAL 26.3400 3 0.0000 NA 
6 rs9296249 ASSOC 25.8700 1 0.0000 NA 
6 rs9296249 HOMOG 0.4634 2 0.7932 NA 
6 rs9296249 1 8.6440 1 0.0033 0.6604 
6 rs9296249 2 9.8720 1 0.0017 0.6335 
6 rs9296249 3 7.8210 1 0.0052 0.5564 
6 rs3923809 TOTAL 32.1700 3 0.0000 NA 
6 rs3923809 ASSOC 30.0900 1 0.0000 NA 
6 rs3923809 HOMOG 2.0840 2 0.3528 NA 
6 rs3923809 1 8.0210 1 0.0046 0.6992 
6 rs3923809 2 12.4900 1 0.0004 0.6309 
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6 rs3923809 3 11.6600 1 0.0006 0.4925 
6 rs4236060 TOTAL 27.7400 3 0.0000 NA 
6 rs4236060 ASSOC 26.6300 1 0.0000 NA 
6 rs4236060 HOMOG 1.1150 2 0.5726 NA 
6 rs4236060 1 6.6790 1 0.0098 0.7106 
6 rs4236060 2 13.6700 1 0.0002 0.6047 
6 rs4236060 3 7.3950 1 0.0065 0.5700 
15 rs11635424 TOTAL 8.3850 3 0.0387 NA 
15 rs11635424 ASSOC 5.2620 1 0.0218 NA 
15 rs11635424 HOMOG 3.1240 2 0.2098 NA 
15 rs11635424 1 5.1000 1 0.0239 0.7622 
15 rs11635424 2 2.7930 1 0.0947 0.8141 
15 rs11635424 3 0.4924 1 0.4829 1.1540 
15 rs3784709 TOTAL 8.3920 3 0.0386 NA 
15 rs3784709 ASSOC 4.7050 1 0.0301 NA 
15 rs3784709 HOMOG 3.6870 2 0.1582 NA 
15 rs3784709 1 4.4100 1 0.0357 0.7763 
15 rs3784709 2 3.1370 1 0.0766 0.8031 
15 rs3784709 3 0.8455 1 0.3578 1.2080 
15 rs1026732 TOTAL 10.4000 3 0.0154 NA 
15 rs1026732 ASSOC 5.8410 1 0.0157 NA 
15 rs1026732 HOMOG 4.5610 2 0.1022 NA 
15 rs1026732 1 6.1260 1 0.0133 0.7417 
15 rs1026732 2 3.2910 1 0.0697 0.7993 
15 rs1026732 3 0.9856 1 0.3208 1.2260 
15 rs6494696 TOTAL 10.5200 3 0.0146 NA 
15 rs6494696 ASSOC 5.9440 1 0.0148 NA 
15 rs6494696 HOMOG 4.5780 2 0.1014 NA 
15 rs6494696 1 6.1260 1 0.0133 0.7417 
15 rs6494696 2 3.4100 1 0.0648 0.7961 
15 rs6494696 3 0.9856 1 0.3208 1.2260 
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Table 6: All tested model based statistics in the combined sample 
TEST TREND – Armitage trend test, REC – recessive model, DOM – dominant model, 
ALLELIC– allelic test (double numbers, individual alleles treated separately), GENO – 
genotypic test comparing both homozygotes and heterozygotes individually, with 2 degrees of 
freedom, AFF – distribution for the given test in affected patients, UNAFF – distribution in 
controls, CHISQ – the actual value of chi-square statistic. DF – number of degrees of freedom, 
P – nominal P values. 
 
CHR SNP TEST AFF UNAFF CHISQ DF P 
2 rs6710341 GENO 4/64/207 11/98/303 NA NA NA 
2 rs6710341 TREND 72/478 120/704 0.5835 1 0.4449 
2 rs6710341 ALLELIC 72/478 120/704 0.5947 1 0.4406 
2 rs6710341 DOM 68/207 109/303 NA NA NA 
2 rs6710341 REC 4/271 11/401 NA NA NA 
2 rs12469063 GENO 22/120/134 18/143/251 11.1000 2 0.0031 
2 rs12469063 TREND 164/388 179/645 11.5100 1 0.0007 
2 rs12469063 ALLELIC 164/388 179/645 11.2700 1 0.0008 
2 rs12469063 DOM 142/134 161/251 10.2600 1 0.0014 
2 rs12469063 REC 22/254 18/394 3.9160 1 0.0478 
2 rs2300478 GENO 22/123/131 18/146/248 12.7000 2 0.0024 
2 rs2300478 TREND 167/385 182/642 12.4000 1 0.0005 
2 rs2300478 ALLELIC 167/385 182/642 11.6400 1 0.0006 
2 rs2300478 DOM 145/131 164/248 10.8300 1 0.0010 
2 rs2300478 REC 22/254 18/394 3.9160 1 0.0478 
6 rs9296249 GENO 8/75/193 22/146/244 8.7540 2 0.0126 
6 rs9296249 TREND 91/461 190/634 8.6860 1 0.0032 
6 rs9296249 ALLELIC 91/461 190/634 8.7870 1 0.0030 
6 rs9296249 DOM 83/193 168/244 8.1720 1 0.0043 
6 rs9296249 REC 8/268 22/390 2.3620 1 0.1243 
6 rs3923809 GENO 16/95/165 44/159/209 7.7900 2 0.0204 
6 rs3923809 TREND 127/425 247/577 7.5980 1 0.0058 
6 rs3923809 ALLELIC 127/425 247/577 8.1100 1 0.0044 
6 rs3923809 DOM 111/165 203/209 5.4620 1 0.0194 
6 rs3923809 REC 16/260 44/368 4.9500 1 0.0261 
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6 rs4236060 GENO 13/87/176 30/153/217 6.6260 2 0.0364 
6 rs4236060 TREND 113/439 213/587 6.5640 1 0.0104 
6 rs4236060 ALLELIC 113/439 213/587 6.7600 1 0.0093 
6 rs4236060 DOM 100/176 183/217 6.0790 1 0.0137 
6 rs4236060 REC 13/263 30/370 2.1340 1 0.1441 
15 rs11635424 GENO 28/97/151 48/180/184 6.7650 2 0.0340 
15 rs11635424 TREND 153/399 276/548 4.8430 1 0.0278 
15 rs11635424 ALLELIC 153/399 276/548 5.1430 1 0.0233 
15 rs11635424 DOM 125/151 228/184 6.6820 1 0.0097 
15 rs11635424 REC 28/248 48/364 0.3813 1 0.5369 
15 rs3784709 GENO 28/96/152 46/179/187 6.4100 2 0.0406 
15 rs3784709 TREND 152/400 271/553 4.1900 1 0.0407 
15 rs3784709 ALLELIC 152/400 271/553 4.4470 1 0.0350 
15 rs3784709 DOM 124/152 225/187 6.2010 1 0.0128 
15 rs3784709 REC 28/248 46/366 0.1792 1 0.6721 
15 rs1026732 GENO 28/94/154 48/180/184 8.3620 2 0.0153 
15 rs1026732 TREND 150/402 276/548 5.7840 1 0.0162 
15 rs1026732 ALLELIC 150/402 276/548 6.1800 1 0.0129 
15 rs1026732 DOM 122/154 228/184 8.2020 1 0.0042 
15 rs1026732 REC 28/248 48/364 0.3813 1 0.5369 
15 rs6494696 GENO 28/94/154 48/180/184 8.3620 2 0.0153 
15 rs6494696 TREND 150/402 276/548 5.7840 1 0.0162 
15 rs6494696 ALLELIC 150/402 276/548 6.1800 1 0.0129 
15 rs6494696 DOM 122/154 228/184 8.2020 1 0.0042 
15 rs6494696 REC 28/248 48/364 0.3813 1 0.5369 
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2) Genetics of secondary RLS form in patients with multiple 
sclerosis 
A. Testing of MS patients positive for RLS versus MS patients negative 
for RLS 
All SNPs tested were in HWE (p>0.01) in both patients and controls. One of the tested 
SNP failed to by-pass genotyping criteria (rs4236060 at BTBD9). After excluding 
patients with probably idiopathic RLS, the power for MEIS1 and BTBD remained 
sufficient – 89.6 and 85.2 respectively. For PTPRD, the power was below 50%, for 
MAP2K5/SCOR1 it was below 70%. 
No significant association with MEIS 1, BTBD9 and PTPRD was found in 203 patients 
with multiple sclerosis. There was a trend for association with MAP2K5/SCOR1 – the 
best model for the risk allele was the recessive model (p nominal = 0.0029, p 
permutated after correction = 0.0248, p nominal corrected for 4 loci and 2 models, i.e. 8 
tests = 0.029, odds ratio = 1.60 – 95% CI 1.17 – 2.18). Thus, the one sided p value with 
the direction of the alternative hypothesis given by the original report is p corrected 
0.019. Results for all tested loci are summarized in Table 7, 8. 
Finally, we did the association analysis only in relapse-remitting MS form in order to 
distinguish the MS subtypes. We included 192 MS patients with RLS and 373 MS 
patients without RLS in the analysis after excluding patients who had a family history 
and RLS symptoms before MS onset.  
The results show the same trend for association as when using patients with all MS 
forms, but due to the lower sample size the significance is lower and does not bypass 
correction for multiple testing (Table 7).  
 
B. Testing of MS patients versus population controls and idiopathic RLS 
patients 
When testing MS patients negative for RLS versus population controls and idiopathic 
RLS, one SNP was not available in previously genotyped population controls 
(rs11788684 from PTPRD). Otherwise, no significant differences were found within the 
remaining tested SNP. Maximal observed 
2 
statistics was 1.9 at rs4626664 on 
chromosome 9, all other values were below 1.0. The sample of 438 MS patients without 
RLS symptoms and 450 population controls had 80% power to detect association with 
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MS (assuming prevalence of 0.001) with OR over 1.58 (MAP2K5/SCOR1) (Table 10 
and 13). 
When testing RLS MS patients positive for RLS vs. idiopathic RLS patients, the allele 
frequencies were very similar for MAP2K5/SCOR1 and PTPRD markers - maximal 
observed 
2 
statistics was 0,4. However, idiopathic RLS patients in variants in MEIS 1 
and BTBD9 genes present with different allele frequencies, but this contrast is only 
nominally significant (Table 9 and 12). 
The last performed comparison was of MS patients positive for RLS versus population 
controls shows similar results and in the same directions, as when comparing to MS 
patients negative for RLS. However the statistical significance is lower, because the 
blood donor were not screened for presence of RLS and have different sex and age 
distribution. (Table 11 and 14) 
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Table 7 Results of genetic association study 
Genome – The Genetic positions in bp derived from UCSC Genome browser (http://genome.ucsc.edu, assembly March 2006) (89) , OR best model – 
Odds-ratio according to best model in original locus description (Allelic for TREND, Allele negativity for REC) including 95% confidence interval. 
MAF MS+RLS+ - minor allele frequency in MS patients with RLS symptoms, MAF MS+RLS- - minor allele frequency in MS patients without RLS 
symptoms, MAF controls – minor allele frequency in unscreened population sample of blood donors. Best model – Best model corresponds to the 
model under which the lowest P values were observed (TREND – Armitage trend test, REC – recessive model) in the original and replication 
publications. (1) P-nom model – raw nominal p-values observed under the best model, P nom allelic – comparison of allele frequencies between MS+ 
RLS+ and MS+RLS- patients. P nom Model RR-MS – raw nominal p-values observed under the best model using relapse-remitting MS patients.  All 
p-values shown are 2-sided. † risk allele is the major allele. 
Chr Gene SNP ID Genome 
OR best model 

















2p MEIS1 Rs6710341 66611926 1.19 (0.86 - 1.64) 0.1533 0.1323 0.1407 TREND 0.4552 0.2954 0.3861 
2p MEIS1 rs12469063 66617812 1.12 (0.86 - 1.45) 0.2588 0.2384 0.2194 TREND 0.3887 0.4128 0.4660 
2p MEIS1 Rs2300478 66634956 1.13 (0.87 - 1.47) 0.2622 0.2396 0.2229 TREND 0.3767 0.3668 0.4000 
6p BTBD9 Rs9296249 38473818 1.14 (0.86 - 1.5) † 0.2102 0.2326 0.2361 TREND 0.1519 0.3541 0.3084 
6p BTBD9 Rs3923809 38548947 1.03 (0.8 - 1.32) † 0.2978 0.3037 0.3060 TREND 0.5883 0.8235 0.7501 
9p PTPRD rs11788684 8846420 1.01 (0.73 - 1.4) 0.1422 0.1407 NA TREND 0.5714 0.9400 0.3782 
9p PTPRD Rs4626664 9261737 1.15 (0.84 - 1.58) † 0.1467 0.1655 0.1409 TREND 0.4507 0.3762 0.8330 
15q MAP2K5 rs11635424 65824631 1.53 (1.12 - 2.08) † 0.2788 0.3341 0.3349 REC 0.0070 0.0402 0.0355 
15q MAP2K5 Rs3784709 65859328 1.60 (1.17 - 2.18) † 0.2765 0.3345 0.3291 REC 0.0029 0.0316 0.0167 
15q MAP2K5 Rs1026732 65882138 1.54 (1.13 - 2.10) † 0.2753 0.3314 0.3349 REC 0.0059 0.0367 0.0272 
15q MAP2K5/ SCOR1 Rs6494696 65890259 1.56 (1.15 - 2.13) † 0.2765 0.3329 0.3356 REC 0.0045 0.0361 0.0253 
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Table 8: Results of model based association in MS patients RLS + vs. RLS – 
TEST  TREND – Armitage trend test, REC – recessive model, DOM – dominant model, 
ALLELIC– allelic test (double numbers, individual alleles treated separately), GENO – 
genotypic test comparing both homozygotes and heterozygotes individually, with 2 degrees of 
freedom, AFF – distribution for the given test in MS+RLS+ patients, UNAFF – distribution in 
MS+RLS-, CHISQ – the actual value of chi-square statistic. DF – number of degrees of 
freedom, P – nominal P values. 
 
CHR SNP TEST AFF UNAFF CHISQ DF P 
2 rs6710341 GENO 9/51/165 15/84/332 1.101 2 0.5767 
2 rs6710341 TREND 69/381 114/748 0.9581 1 0.3277 
2 rs6710341 ALLELIC 69/381 114/748 1.095 1 0.2954 
2 rs6710341 DOM 60/165 99/332 1.1 1 0.2942 
2 rs6710341 REC 9/216 15/416 0.1133 1 0.7364 
2 rs12469063 GENO 16/85/125 23/159/248 0.9082 2 0.635 
2 rs12469063 TREND 117/335 205/655 0.6737 1 0.4118 
2 rs12469063 ALLELIC 117/335 205/655 0.6709 1 0.4128 
2 rs12469063 DOM 101/125 182/248 0.3377 1 0.5612 
2 rs12469063 REC 16/210 23/407 0.7937 1 0.373 
2 rs2300478 GENO 17/84/124 23/161/248 1.348 2 0.5097 
2 rs2300478 TREND 118/332 207/657 0.8159 1 0.3664 
2 rs2300478 ALLELIC 118/332 207/657 0.8146 1 0.3668 
2 rs2300478 DOM 101/124 184/248 0.3176 1 0.573 
2 rs2300478 REC 17/208 23/409 1.288 1 0.2563 
2 rs11683508 GENO 6/70/149 15/128/286 0.4001 2 0.8187 
2 rs11683508 TREND 82/368 158/700 0.007393 1 0.9315 
2 rs11683508 ALLELIC 82/368 158/700 0.007316 1 0.9318 
2 rs11683508 DOM 76/149 143/286 0.01309 1 0.9089 
2 rs11683508 REC 6/219 15/414 0.327 1 0.5674 
6 rs9296249 GENO 10/75/141 32/137/263 2.223 2 0.3291 
6 rs9296249 TREND 95/357 201/663 0.7982 1 0.3716 
6 rs9296249 ALLELIC 95/357 201/663 0.8588 1 0.3541 
6 rs9296249 DOM 85/141 169/263 0.1427 1 0.7056 
6 rs9296249 REC 10/216 32/400 2.209 1 0.1372 
6 rs3923809 GENO 19/96/110 46/168/214 1.248 2 0.5358 
6 rs3923809 TREND 134/316 260/596 0.04781 1 0.8269 
6 rs3923809 ALLELIC 134/316 260/596 0.04974 1 0.8235 
6 rs3923809 DOM 115/110 214/214 0.07283 1 0.7873 
6 rs3923809 REC 19/206 46/382 0.8728 1 0.3502 
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9 rs11788684 GENO 6/52/167 7/107/316 1.005 2 0.605 
9 rs11788684 TREND 64/386 121/739 0.005666 1 0.94 
9 rs11788684 ALLELIC 64/386 121/739 0.005662 1 0.94 
9 rs11788684 DOM 58/167 114/316 0.04108 1 0.8394 
9 rs11788684 REC 6/219 7/423 0.8193 1 0.3654 
9 rs4626664 GENO 5/56/164 11/120/298 0.8369 2 0.6581 
9 rs4626664 TREND 66/384 142/716 0.7878 1 0.3748 
9 rs4626664 ALLELIC 66/384 142/716 0.783 1 0.3762 
9 rs4626664 DOM 61/164 131/298 0.8348 1 0.3609 
9 rs4626664 REC 5/220 11/418 0.07228 1 0.788 
15 rs11635424 GENO 20/86/120 39/210/182 7.565 2 0.02277 
15 rs11635424 TREND 126/326 288/574 4.402 1 0.0359 
15 rs11635424 ALLELIC 126/326 288/574 4.209 1 0.04021 
15 rs11635424 DOM 106/120 249/182 7.053 1 0.007913 
15 rs11635424 REC 20/206 39/392 0.007195 1 0.9324 
15 rs3784709 GENO 20/85/121 38/213/181 8.863 2 0.0119 
15 rs3784709 TREND 125/327 289/575 4.865 1 0.02741 
15 rs3784709 ALLELIC 125/327 289/575 4.621 1 0.03159 
15 rs3784709 DOM 105/121 251/181 8.098 1 0.004431 
15 rs3784709 REC 20/206 38/394 0.000524 1 0.9817 
15 rs1026732 GENO 20/85/122 39/209/185 7.81 2 0.02014 
15 rs1026732 TREND 125/329 287/579 4.532 1 0.03326 
15 rs1026732 ALLELIC 125/329 287/579 4.363 1 0.03673 
15 rs1026732 DOM 105/122 248/185 7.269 1 0.007017 
15 rs1026732 REC 20/207 39/394 0.007054 1 0.9331 
15 rs6494696 GENO 20/85/121 39/211/184 8.011 2 0.01821 
15 rs6494696 TREND 125/327 289/579 4.583 1 0.03229 
15 rs6494696 ALLELIC 125/327 289/579 4.392 1 0.03611 
15 rs6494696 DOM 105/121 250/184 7.424 1 0.006435 
15 rs6494696 REC 20/206 39/395 0.003407 1 0.9535 
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Table 9: Comparison of secondary RLS in MS vs. idiopathic RLS patients, allelic 
association 
BP – The Genetic positions in bp derived from UCSC Genome browser 
(http://genome.ucsc.edu, assembly March 2006) (89), MAF MS+RLS+ - minor allele 
frequency in MS patients with RLS symptoms, MAF RLS- - minor allele frequency in 
idiopathic patients, Czech sample, CHISQ – the actual value of chi-square statistic. P – nominal 
P values, OR – Odds-ratio according to allelic test. 
 
CHR SNP BP MAF 
MS+RLS+ 
MAF RLS CHISQ P OR 
2 Rs6710341 66611926 0.1553 0.1295 2.189 0.139 1.236 
2 Rs12469063 66617812 0.2594 0.3061 4.144 0.04178 0.7939 
2 Rs2300478 66634957 0.2628 0.3152 5.126 0.02357 0.7746 
6 Rs9296249 38473819 0.2 0.1754 1.585 0.2081 1.175 
6 Rs3923809 38548948 0.2799 0.2329 4.612 0.03174 1.28 
9 Rs4626664 9251737 0.1565 0.1689 0.443 0.5057 0.9125 
15 Rs11635424 65824632 0.284 0.281 0.01777 0.8939 1.015 
15 Rs3784709 65859329 0.2772 0.2776 0.00028 0.9867 0.9981 
15 Rs1026732 65882139 0.2787 0.2771 0.005017 0.9435 1.008 
15 Rs6494696 65890260 0.2789 0.2767 0.009224 0.9235 1.011 
 
 53 
Table 10: Comparison of MS patients without RLS vs. population controls, allelic 
association 
BP – The Genetic positions in bp derived from UCSC Genome browser 
(http://genome.ucsc.edu, assembly March 2006) (89), MAF MS+RLS- - minor allele frequency 
in MS patients without RLS symptoms, MAF Controls- - minor allele frequency in population 
based controls (blood donors), CHISQ – the actual value of chi-square statistic. P – nominal P 
values. 
 




Controls CHISQ P 
2 rs6710341 66611926 0.1331 0.147 0.6801 0.4096 
2 rs12469063 66617812 0.2392 0.2194 0.9403 0.3322 
2 rs2300478 66634957 0.2404 0.2229 0.7379 0.3903 
6 rs9296249 38473819 0.2368 0.2361 0.0013 0.9717 
6 rs3923809 38548948 0.3104 0.306 0.0381 0.8452 
9 rs4626664 9251737 0.1651 0.1409 1.9150 0.1664 
15 rs11635424 65824632 0.3381 0.3349 0.0202 0.8870 
15 rs3784709 65859329 0.3385 0.3291 0.1697 0.6804 
15 rs1026732 65882139 0.3353 0.3349 0.0004 0.9843 
15 rs6494696 65890260 0.3369 0.3356 0.0030 0.9562 
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Table 11: Comparison of MS patients with RLS vs. population controls, allelic 
association 
BP – The Genetic positions in bp derived from UCSC Genome browser 
(http://genome.ucsc.edu, assembly March 2006) (89) , MAF MS+RLS+ – minor allele 
frequency in MS patients with RLS symptoms, MAF Controls- – minor allele frequency in 
population based controls (blood donors), CHISQ – the actual value of chi-square statistic, P – 
nominal P values, OR – Odds-ratio according to allelic test 
 
CHR SNP BP MS+RLS+ Controls CHISQ P OR 
2 rs6710341 66611926 0.1553 0.147 0.1883 0.6644 1.0670 
2 rs12469063 66617812 0.2594 0.2194 3.103 0.0781 1.2460 
2 rs2300478 66634957 0.2628 0.2229 3.065 0.0800 1.2430 
6 rs9296249 38473819 0.2 0.2361 2.652 0.1034 0.8088 
6 rs3923809 38548948 0.2799 0.306 1.147 0.2841 0.8814 
9 rs4626664 9251737 0.1565 0.1409 0.6777 0.4104 1.1310 
15 rs11635424 65824632 0.284 0.3349 4.203 0.0404 0.7879 
15 rs3784709 65859329 0.2772 0.3291 4.423 0.0355 0.7819 
15 rs1026732 65882139 0.2787 0.3349 5.165 0.0230 0.7675 
15 rs6494696 65890260 0.2789 0.3356 5.241 0.0221 0.7656 
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Table 12: Comparison of secondary RLS in MS vs. idiopathic RLS patients, 
genotypic (model based) association 
TEST  TREND – Armitage trend test, REC – recessive model, DOM – dominant model, 
ALLELIC – allelic test (double numbers, individual alleles treated separately), GENO – 
genotypic test comparing both homozygotes and heterozygotes individually, with 2 degrees of 
freedom, MS+RLS+ – test distribution in MS patients with RLS symptoms, RLS- – test 
distribution in idiopathic patients, Czech sample –, CHISQ – the actual value of chi-square 
statistic. DF – number of degrees of freedom, P – nominal P values. 
 
CHR SNP TEST MS+RLS+ RLS CHISQ P 
2 rs6710341 GENO 13/65/215 12/128/447 4.1500 0.1255 
2 rs6710341 TREND 91/495 152/1022 2.0300 0.1542 
2 rs6710341 ALLELIC 91/495 152/1022 2.1890 0.1390 
2 rs6710341 DOM 78/215 140/447 0.8053 0.3695 
2 rs6710341 REC 13/280 12/575 4.0530 0.0441 
2 rs12469063 GENO 20/112/161 56/248/284 4.1090 0.1282 
2 rs12469063 TREND 152/434 360/816 4.1080 0.0427 
2 rs12469063 ALLELIC 152/434 360/816 4.1440 0.0418 
2 rs12469063 DOM 132/161 304/284 3.4590 0.0629 
2 rs12469063 REC 20/273 56/532 1.8060 0.1790 
2 rs2300478 GENO 21/112/160 59/252/276 5.1060 0.0779 
2 rs2300478 TREND 154/432 370/804 5.0710 0.0243 
2 rs2300478 ALLELIC 154/432 370/804 5.1260 0.0236 
2 rs2300478 DOM 133/160 311/276 4.5030 0.0338 
2 rs2300478 REC 21/272 59/528 1.9670 0.1608 
6 rs9296249 GENO 14/90/191 18/171/401 2.0230 0.3638 
6 rs9296249 TREND 118/472 207/973 1.5590 0.2117 
6 rs9296249 ALLELIC 118/472 207/973 1.5850 0.2081 
6 rs9296249 DOM 104/191 189/401 0.9209 0.3372 
6 rs9296249 REC 14/281 18/572 1.6210 0.2029 
6 rs3923809 GENO 24/116/153 31/210/343 4.7420 0.0934 
6 rs3923809 TREND 164/422 272/896 4.5900 0.0322 
6 rs3923809 ALLELIC 164/422 272/896 4.6120 0.0317 
6 rs3923809 DOM 140/153 241/343 3.3700 0.0664 
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6 rs3923809 REC 24/269 31/553 2.7590 0.0967 
9 rs4626664 GENO 9/74/211 22/155/412 0.4450 0.8005 
9 rs4626664 TREND 92/496 199/979 0.4188 0.5175 
9 rs4626664 ALLELIC 92/496 199/979 0.4430 0.5057 
9 rs4626664 DOM 83/211 177/412 0.3126 0.5761 
9 rs4626664 REC 9/285 22/567 0.2629 0.6081 
15 rs11635424 GENO 25/117/152 57/217/315 0.8609 0.6502 
15 rs11635424 TREND 167/421 331/847 0.0167 0.8973 
15 rs11635424 ALLELIC 167/421 331/847 0.0178 0.8939 
15 rs11635424 DOM 142/152 274/315 0.2493 0.6176 
15 rs11635424 REC 25/269 57/532 0.3209 0.5711 
15 rs3784709 GENO 25/113/156 59/209/321 1.0160 0.6018 
15 rs3784709 TREND 163/425 327/851 0.0003 0.9872 
15 rs3784709 ALLELIC 163/425 327/851 0.0003 0.9867 
15 rs3784709 DOM 138/156 268/321 0.1632 0.6862 
15 rs3784709 REC 25/269 59/530 0.5219 0.4700 
15 rs1026732 GENO 25/115/156 58/211/321 1.0210 0.6003 
15 rs1026732 TREND 165/427 327/853 0.0046 0.9457 
15 rs1026732 ALLELIC 165/427 327/853 0.0050 0.9435 
15 rs1026732 DOM 140/156 269/321 0.2303 0.6313 
15 rs1026732 REC 25/271 58/532 0.4451 0.5047 
15 rs6494696 GENO 25/114/155 58/210/321 1.0130 0.6027 
15 rs6494696 TREND 164/424 326/852 0.0085 0.9265 
15 rs6494696 ALLELIC 164/424 326/852 0.0092 0.9235 
15 rs6494696 DOM 139/155 268/321 0.2495 0.6174 




Table 13: Comparison of MS patients without RLS vs. population controls, 
genotypic (model based) association 
TEST TREND – Armitage trend test, REC – recessive model, DOM – dominant model, 
ALLELIC – allelic test (double numbers, individual alleles treated separately), GENO – 
genotypic test comparing both homozygotes and heterozygotes individually, with 2 degrees of 
freedom, MS+RLS- – test distribution in MS patients without RLS symptoms, Controls- – test 
distribution in population controls (blood donors), CHISQ – the actual value of chi-square statistic. 
DF– number of degrees of freedom, P – nominal P values. 
 
CHR SNP TEST MS+RLS- Controls CHISQ P 
2 rs6710341 GENO 14/83/320 11/105/316 2.6950 0.2598 
2 rs6710341 TREND 111/723 127/737 0.6289 0.4278 
2 rs6710341 ALLELIC 111/723 127/737 0.6801 0.4096 
2 rs6710341 DOM 97/320 116/316 1.4550 0.2277 
2 rs6710341 REC 14/403 11/421 0.4883 0.4847 
2 rs12469063 GENO 22/155/239 19/152/262 0.9647 0.6173 
2 rs12469063 TREND 199/633 190/676 0.9632 0.3264 
2 rs12469063 ALLELIC 199/633 190/676 0.9403 0.3322 
2 rs12469063 DOM 177/239 171/262 0.8193 0.3654 
2 rs12469063 REC 22/394 19/414 0.3743 0.5407 
2 rs2300478 GENO 22/157/239 19/155/259 0.7714 0.6800 
2 rs2300478 TREND 201/635 193/673 0.7610 0.3830 
2 rs2300478 ALLELIC 201/635 193/673 0.7379 0.3903 
2 rs2300478 DOM 179/239 174/259 0.6098 0.4349 
2 rs2300478 REC 22/396 19/414 0.3552 0.5512 
6 rs9296249 GENO 31/136/251 24/156/252 2.0330 0.3619 
6 rs9296249 TREND 198/638 204/660 0.0012 0.9724 
6 rs9296249 ALLELIC 198/638 204/660 0.0013 0.9717 
6 rs9296249 DOM 167/251 180/252 0.2585 0.6112 
6 rs9296249 REC 31/387 24/408 1.2150 0.2703 
6 rs3923809 GENO 46/165/203 48/169/216 0.0676 0.9668 
6 rs3923809 TREND 257/571 265/601 0.0355 0.8506 
6 rs3923809 ALLELIC 257/571 265/601 0.0381 0.8452 
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6 rs3923809 DOM 211/203 217/216 0.0613 0.8045 
6 rs3923809 REC 46/368 48/385 0.0001 0.9905 
9 rs4626664 GENO 11/115/289 10/102/321 2.1240 0.3458 
9 rs4626664 TREND 137/693 122/744 1.8940 0.1687 
9 rs4626664 ALLELIC 137/693 122/744 1.9150 0.1664 
9 rs4626664 DOM 126/289 112/321 2.1210 0.1453 
9 rs4626664 REC 11/404 10/423 0.1021 0.7493 
15 rs11635424 GENO 38/206/173 50/190/193 3.0760 0.2148 
15 rs11635424 TREND 282/552 290/576 0.0211 0.8845 
15 rs11635424 ALLELIC 282/552 290/576 0.0202 0.8870 
15 rs11635424 DOM 244/173 240/193 0.8251 0.3637 
15 rs11635424 REC 38/379 50/383 1.3570 0.2441 
15 rs3784709 GENO 37/209/172 48/189/196 3.7310 0.1549 
15 rs3784709 TREND 283/553 285/581 0.1789 0.6723 
15 rs3784709 ALLELIC 283/553 285/581 0.1697 0.6804 
15 rs3784709 DOM 246/172 237/196 1.4690 0.2255 
15 rs3784709 REC 37/381 48/385 1.1800 0.2773 
15 rs1026732 GENO 38/205/176 50/190/193 2.7600 0.2516 
15 rs1026732 TREND 281/557 290/576 0.0004 0.9840 
15 rs1026732 ALLELIC 281/557 290/576 0.0004 0.9843 
15 rs1026732 DOM 243/176 240/193 0.5719 0.4495 
15 rs1026732 REC 38/381 50/383 1.4120 0.2347 
15 rs6494696 GENO 38/207/175 50/190/192 2.9830 0.2250 
15 rs6494696 TREND 283/557 290/574 0.0032 0.9552 
15 rs6494696 ALLELIC 283/557 290/574 0.0030 0.9562 
15 rs6494696 DOM 245/175 240/192 0.6701 0.4130 
15 rs6494696 REC 38/382 50/382 1.4680 0.2257 
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Table 14: Comparison of MS patients with RLS vs. population controls, genotypic 
(model based) association 
TEST  TREND – Armitage trend test, REC – recessive model, DOM – dominant model, 
ALLELIC – allelic test (double numbers, individual alleles treated separately), GENO – 
genotypic test comparing both homozygotes and heterozygotes individually, with 2 degrees of 
freedom, MS+RLS+ – test distribution in MS patients with RLS symptoms, Controls- – test 
distribution in population controls (blood donors), CHISQ – the actual value of chi-square 
statistic. DF – number of degrees of freedom, P – nominal P values. 
 
CHR SNP TEST MS+RLS+ Controls CHISQ P 
2 rs6710341 GENO 13/65/215 11/105/316 2.2210 0.3293 
2 rs6710341 TREND 91/495 127/737 0.1740 0.6766 
2 rs6710341 ALLELIC 91/495 127/737 0.1883 0.6644 
2 rs6710341 DOM 78/215 116/316 0.0047 0.9451 
2 rs6710341 REC 13/280 11/421 1.9500 0.1626 
2 rs12469063 GENO 20/112/161 19/152/262 3.3290 0.1893 
2 rs12469063 TREND 152/434 190/676 3.1340 0.0767 
2 rs12469063 ALLELIC 152/434 190/676 3.1030 0.0781 
2 rs12469063 DOM 132/161 171/262 2.2210 0.1361 
2 rs12469063 REC 20/273 19/414 2.0430 0.1529 
2 rs2300478 GENO 21/112/160 19/155/259 3.5510 0.1694 
2 rs2300478 TREND 154/432 193/673 3.0990 0.0783 
2 rs2300478 ALLELIC 154/432 193/673 3.0650 0.0800 
2 rs2300478 DOM 133/160 174/259 1.9420 0.1635 
2 rs2300478 REC 21/272 19/414 2.5930 0.1074 
6 rs9296249 GENO 14/90/191 24/156/252 3.0290 0.2199 
6 rs9296249 TREND 118/472 204/660 2.6030 0.1067 
6 rs9296249 ALLELIC 118/472 204/660 2.6520 0.1034 
6 rs9296249 DOM 104/191 180/252 3.0280 0.0818 
6 rs9296249 REC 14/281 24/408 0.2321 0.6300 
6 rs3923809 GENO 24/116/153 48/169/216 1.6770 0.4323 
6 rs3923809 TREND 164/422 265/601 1.0850 0.2975 
6 rs3923809 ALLELIC 164/422 265/601 1.1470 0.2841 
6 rs3923809 DOM 140/153 217/216 0.3809 0.5371 
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6 rs3923809 REC 24/269 48/385 1.6390 0.2005 
9 rs4626664 GENO 9/74/211 10/102/321 0.7008 0.7044 
9 rs4626664 TREND 92/496 122/744 0.6544 0.4186 
9 rs4626664 ALLELIC 92/496 122/744 0.6777 0.4104 
9 rs4626664 DOM 83/211 112/321 0.4991 0.4799 
9 rs4626664 REC 9/285 10/423 0.3888 0.5329 
15 rs11635424 GENO 25/117/152 50/190/193 4.1390 0.1262 
15 rs11635424 TREND 167/421 290/576 4.1200 0.0424 
15 rs11635424 ALLELIC 167/421 290/576 4.2030 0.0404 
15 rs11635424 DOM 142/152 240/193 3.5680 0.0589 
15 rs11635424 REC 25/269 50/383 1.7540 0.1854 
15 rs3784709 GENO 25/113/156 48/189/196 4.5060 0.1051 
15 rs3784709 TREND 163/425 285/581 4.3120 0.0378 
15 rs3784709 ALLELIC 163/425 285/581 4.4230 0.0355 
15 rs3784709 DOM 138/156 237/196 4.2610 0.0390 
15 rs3784709 REC 25/269 48/385 1.2920 0.2556 
15 rs1026732 GENO 25/115/156 50/190/193 5.1340 0.0768 
15 rs1026732 TREND 165/427 290/576 5.0360 0.0248 
15 rs1026732 ALLELIC 165/427 290/576 5.1650 0.0230 
15 rs1026732 DOM 140/156 240/193 4.6570 0.0309 
15 rs1026732 REC 25/271 50/383 1.8320 0.1759 
15 rs6494696 GENO 25/114/155 50/190/192 5.2360 0.0729 
15 rs6494696 TREND 164/424 290/574 5.1090 0.0238 
15 rs6494696 ALLELIC 164/424 290/574 5.2410 0.0221 
15 rs6494696 DOM 139/155 240/192 4.8030 0.0284 
15 rs6494696 REC 25/269 50/382 1.7810 0.1821 
 61 
DISCUSSION 
In our work, we wanted to further investigate clinical and genetic aspects of primary 
and secondary RLS.   
The aim of the clinical part was to verify the high prevalence of RLS among Czech 
patients with multiple sclerosis, to identify the risk factors for RLS and correlation of 
magnetic resonance imaging parameters with RLS in patients with MS. 
In the clinical part, we confirmed the previous findings that the prevalence of RLS is 
high in patients with MS. 
An earlier study investigating the association between RLS and MS in the French-
Canadian population showed a difference in prevalence between patients and controls of 
37.5% vs. 16% (76). A later study published by an Italian group showed a prevalence of 
19% in MS and 4.2% in control subjects (78). They did not include patients who 
experienced the symptoms with a frequency of occurrence lower than twice per week (a 
further 7.3%, total RLS prevalence 26.3%). Another study published by Spanish authors 
showed different results – a similar prevalence rate of RLS in MS patients and in 
healthy subjects (13.3% vs. 9.3%) (77). A different methodology and different 
frequency criteria might explain the discrepancies in absolute values in estimation of 
prevalence rates among these studies. In our study, we did not use any frequency 
threshold for the diagnosis of RLS: a patient was considered to be affected if he/she had 
ever met all criteria in their lifetime. The total prevalence was 32%, and in 68 (8.8%) 
subjects the RLS symptoms preceded the MS onset and 19 patients (2.4% of total) from 
this group reported a positive family history. Thus our estimate of the prevalence of 
RLS is very similar to those observed in the larger studies. 
In patients with MS, among others, the following risk factors for RLS were found: older 
age, longer MS duration and higher neurological disability; therefore, the patients with 
RLS seem to be in a more advanced stage of MS as was previously suggested (78).  
We conclude that RLS is significantly associated with MS and can lead to sleep 
disturbance in MS patients. In clinical praxis, we encouraged the routine screening of 
patients for insomnia and symptoms of RLS. However, patients with MS often report 
sensitive symptoms (dysaesthesia and paraesthesia, spasticity) and it is important to 
clearly differentiate between RLS and neurological symptoms not associated with RLS. 
We therefore stress that all the essential criteria should be met and patients should be 
personally interviewed to avoid false-positive diagnosis. 
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The radiological study has also confirmed the previous investigations of Manconi et al. 
that the presence of RLS symptoms does not correlate with MRI markers of brain 
damage in MS despite the fact that RLS is more prevalent in advanced stages of MS. 
We used MRI volume parameters which better correlate with the MS clinical 
progression. The results may be caused by the low sensitivity of our MRI analysis 
approach, however Manconi et al. assessed more specific scans with mean diffusion 
(MD) and fractional anisotropy (FA) analysis and found no association between RLS 
and a particular brain MRI lesion pattern (79). The study revealed significantly reduced 
cervical cord average FA in MS patients with RLS compared to those without. Cervical 
cord damage may play a role in the pathophysiology of the association between RLS 
and MS. The cord damage may interrupt descending or ascending pathways and this 
could lead to a higher spinal motor excitability in RLS patients, this is supported by 
several clinical and neurophysiological studies (91). The possible target may be the A 
11 dopaminergic diencephalon pathways projecting from the A 11 hypothalamic area to 
D3 receptors located in the dorsal and intermediolateralis spinal nuclei (33). 
 
 
Picture 5: Spinal cord lesions in MS patients 
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Our second study, “Replication in three populations” showed an association of common 
genetic variants in MEIS1, BTBD9 and MAP2K5/SCOR1 with RLS in a combined 
sample of Czech, Austrian, and Finnish RLS cases. Similar findings were observed in 
the US population (65). In accordance to the original report, the strongest effect was 
observed with the haplotype “AG” formed by markers rs6710341 and rs12469063 
located in the 9
th
 intron of MEIS1, providing ORs of about 2.0 for this haplotype. 
However, the OR may be underestimated, because the controls samples were not 
screened to exclude RLS and therefore may contain approximately 10% of individuals 
actually affected by RLS. The best models observed for individual loci are in good 
agreement with previous findings in German and Canadian populations (64). The 
significance of these loci to RLS can therefore be regarded as well established.  
The sub-analysis in Czech and Austrian populations show the same trends for 
association as the combined sample, but in the Finnish sample, only association with 
BTBD9 was confirmed and there was a trend for association to MEIS1. Moreover, the 
allele frequencies and proportions of familial cases in the Finnish sample were different 
from the other two, but the smaller size of this sample limits further implications. 
In our sample set we have not observed significant differences between familial and 
sporadic cases concerning the BTBD9 locus. The 95% confidence intervals of OR also 
overlapped between familial and sporadic cases for both MEIS1 (1.357 – 2.1 in familial 
and 1.019 – 1.534 in sporadic cases vs. all controls for rs12469063) and 
MAP2K5/SCOR1 (1.164 – 1.841 in familial and 0.951 – 1.408 in sporadic cases for 
rs6494696). There is a trend that MEIS1 and MAP2K5/SCOR1 possibly play a more 
important role in familial RLS, but due to limited number of patients, we were not able 
to prove significant heterogeneity. Generally the risk alleles in these loci are common 
and exert only small to moderate effects. They do not explain the familial clustering of 
RLS. Among the known loci, BTBD9 seems to be the most consistent in its effect on 
RLS across populations and is also most independent of familial clustering. We 
conclude that the observed genetic determinants are risk factors for RLS in multiple 
populations. Further studies including genotyping with genome-wide SNP Arrays might 
give us a more comprehensive picture and answer the question as to whether further 
genetics factors besides the known RLS factors are involved.  
The last part of the genetic study “Genetics of secondary RLS form in patients with 
MS” attempted to reveal whether the genetic variants known to increase the risk in 
idiopathic RLS cases (MEIS1, BTBD9, MAP2K5/SCOR1, PTPRD) also contribute to the 
secondary RLS in patients with multiple sclerosis. So far only one genetic association 
study with secondary RLS cases has been published (72). 
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Our study, despite its sufficient statistical power, showed no association to variants in 
MEIS1 and BTBD9 with secondary RLS in MS patients. There was a trend for the 
association with MAP2K5/SCOR1, the best model was the recessive one. This model 
and the direction of the association are in accordance with the previous genome-wide 
scans and replication studies in idiopathic cases (64, 67).  
To exclude the possible genetic influence of an MS diagnosis we conducted the second 
association study comparing patients suffering with MS without RLS to the unscreened 
population and found no association for all tested variants, taking into account the 
above described statistical power.  
The MAP2K5/SCOR 1 gene variant showed significant evidence for the association in 
the genome-wide scans in idiopathic cases. MAP2K5 is important for the early stages of 
muscle differentiation and is important in the neuroprotection of dopaminergic neurons. 
SCOR 1 acts as a transcriptional co-repressor of LBX1 (64, 92). This homeobox is 
critical in the development of sensory pathways in the dorsal horn of the spinal cord 
(70). Its role and function in RLS as well as in patients with RLS/MS, however, is not 
known. 
Spinal cord is also a common lesion target for autoimmune inflammation in MS. 
Patients with MS may be due to this SCOR1 variant more susceptible to development of 
RLS, in presence of another provoking factor (i.e. lesion in spinal cord). The most 
probable structure can be dopaminergic pathways from the hypothalamic area A 11 to 
dorsal horns in the spinal cord (33). This second-hit theory is supported by findings of 
the older age, longer MS duration and higher disability of MS patients with RLS 
compared to the patients without RLS. However, other genes of smaller effects may 
contribute to this RLS phenotype. 
Further studies with more accurate spinal cord MRI and genetic association with other 
secondary RLS cases, such as in pregnancy, are necessary to disclose the pathogenesis 




A. The prevalence of RLS in patients with MS is high (32% in the 
Czech population), MS should be considered amongst secondary RLS 
forms. RLS is associated with more severe disability and clinical course 
in MS patients.  
We should investigate MS patients for RLS symptoms, if they report 
sleep difficulties, because the effective treatment is available. 
 
B. The extent of brain damage using MRI does not correlate with the 
presence of RLS in MS patients. Therefore, further studies with the 
spinal cord MRI are necessary to disclose the etiopathogenesis 
 
Genetic part 
A. Our study shows that variants in three loci confer consistent 
disease risks in patients of European descent. Among the known loci, 
BTBD9 seems to be the most consistent in its effect on RLS across 
populations and is also most independent of familial clustering. 
 
B. The idiopathic RLS forms do not share all the major genetic 
features with secondary RLS forms in patients with MS. However, we 
were able to confirm the mild impact of the SCOR1 gene variants on a 
higher prevalence of RLS in MS patients. 
 66 
 
LIST OF TABLES 
Table 1: Quantitative brain MRI data from MS-patients) without RLS (MS/RLS-) and 
with RLS (MS/RLS+) ..................................................................................................... 38 
Table 2: Correlation of MRI data with clinical parameters of MS ................................. 38 
Table 3: Genotyped SNPs and Results of Association in Combined Samples ............... 41 
Table 4: Analysis in individual populations ................................................................... 42 
Table 5: Results of Cochran-Mantel-Haenszel test in all 3 populations ......................... 43 
Table 6: All tested model based statistics in the combined sample ................................ 45 
Table 7 Results of genetic association study .................................................................. 49 
Table 8: Results of model based association in MS patients RLS + vs. RLS – ............. 50 
Table 9: Comparison of secondary RLS in MS vs. idiopathic RLS patients, allelic 
association ....................................................................................................................... 52 
Table 10: Comparison of MS patients without RLS vs. population controls, allelic 
association ....................................................................................................................... 53 
Table 11: Comparison of MS patients with RLS vs. population controls, allelic 
association ....................................................................................................................... 54 
Table 12: Comparison of secondary RLS in MS vs. idiopathic RLS patients, genotypic 
(model based) association ............................................................................................... 55 
Table 13: Comparison of MS patients without RLS vs. population controls, genotypic 
(model based) association ............................................................................................... 57 
Table 14: Comparison of MS patients with RLS vs. population controls, genotypic 




    
 
1. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. 
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A 
report from the restless legs syndrome diagnosis and epidemiology workshop at the 
National Institutes of Health. Sleep Med2003 Mar;4(2):101-19. 
2. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. 
Restless legs syndrome prevalence and impact: REST general population study. Arch 
Intern Med2005 Jun 13;165(11):1286-92. 
3. Ekbom KA. Restless legs syndrome. Neurology1960 Sep;10:868-73. 
4. Chayudhuri KR F-SL, Rye David. Restless legs syndrome. Oxford University 
Press2009. 
5. Kryger MH RT, Dement WC. Principles and Practice of Sleep medicine. 
Elsevier Saunders2005. 
6. Šonka K. Syndrom neklidných nohou. Maxdorf2008. 
7. Michaud M, Chabli A, Lavigne G, Montplaisir J. Arm restlessness in patients 
with restless legs syndrome. Mov Disord2000 Mar;15(2):289-93. 
8. Michaud M, Poirier G, Lavigne G, Montplaisir J. Restless Legs Syndrome: 
scoring criteria for leg movements recorded during the suggested immobilization test. 
Sleep Med2001 Jul;2(4):317-21. 
9. Saletu B, Anderer P, Saletu M, Hauer C, Lindeck-Pozza L, Saletu-Zyhlarz G. 
EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome 
(RLS) and periodic limb movement disorder (PLMD) patients as compared with normal 
controls. Sleep Med2002 Nov;3 Suppl:S35-42. 
10. Hornyak M, Feige B, Voderholzer U, Philipsen A, Riemann D. 
Polysomnography findings in patients with restless legs syndrome and in healthy 
controls: a comparative observational study. Sleep2007 Jul;30(7):861-5. 
11. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. 
Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a 
study of 133 patients diagnosed with new standard criteria. Mov Disord1997 
Jan;12(1):61-5. 
12. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome 
(RLS) using age-of-symptom-onset. Sleep Med2000 Feb 1;1(1):11-9. 
13. Hening WA, Allen RP, Washburn M, Lesage SR, Earley CJ. The four diagnostic 
criteria for Restless Legs Syndrome are unable to exclude confounding conditions 
("mimics"). Sleep Med2009 Oct;10(9):976-81. 
14. Trenkwalder C, Hogl B, Winkelmann J. Recent advances in the diagnosis, 
genetics and treatment of restless legs syndrome. J Neurol2009 Apr;256(4):539-53. 
15. Kemlink D, Pretl M, Sonka K, Nevsimalova S. A comparison of 
polysomnographic and actigraphic evaluation of periodic limb movements in sleep. 
Neurol Res2008 Apr;30(3):234-8. 
16. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. 
Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care 
 68 
population: the REST (RLS epidemiology, symptoms, and treatment) primary care 
study. Sleep Med2004 May;5(3):237-46. 
17. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, et 
al. Treatment of restless legs syndrome: an evidence-based review and implications for 
clinical practice. Mov Disord2008 Dec 15;23(16):2267-302. 
18. Garcia-Borreguero D. Augmentation: understanding a key feature of RLS. Sleep 
Med2004 Jan;5(1):5-6. 
19. Kushida C, Martin M, Nikam P, Blaisdell B, Wallenstein G, Ferini-Strambi L, et 
al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res2007 
May;16(4):617-24. 
20. Pearson VE, Allen RP, Dean T, Gamaldo CE, Lesage SR, Earley CJ. Cognitive 
deficits associated with restless legs syndrome (RLS). Sleep Med2006 Jan;7(1):25-30. 
21. Hornyak M. Depressive disorders in restless legs syndrome: epidemiology, 
pathophysiology and management. CNS Drugs Feb;24(2):89-98. 
22. Innes KE, Selfe TK, Agarwal P. Restless legs syndrome and conditions 
associated with metabolic dysregulation, sympathoadrenal dysfunction, and 
cardiovascular disease risk: A systematic review. Sleep Med Rev Aug;16(4):309-39. 
23. Walters AS, Rye DB. Review of the relationship of restless legs syndrome and 
periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep2009 
May;32(5):589-97. 
24. Kemlink D, Pretl M, Kelemen J, Sonka K, Nevsimalova S. [Periodic limb 
movements in sleep: polysomnographic and actigraphic methods for their detection]. 
Cas Lek Cesk2005;144(10):689-91. 
25. Winkelman JW, Redline S, Baldwin CM, Resnick HE, Newman AB, Gottlieb 
DJ. Polysomnographic and health-related quality of life correlates of restless legs 
syndrome in the Sleep Heart Health Study. Sleep2009 Jun;32(6):772-8. 
26. Zucconi M, Ferri R, Allen R, Baier PC, Bruni O, Chokroverty S, et al. The 
official World Association of Sleep Medicine (WASM) standards for recording and 
scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed 
in collaboration with a task force from the International Restless Legs Syndrome Study 
Group (IRLSSG). Sleep Med2006 Mar;7(2):175-83. 
27. Hornyak M, Feige B, Riemann D, Voderholzer U. Periodic leg movements in 
sleep and periodic limb movement disorder: prevalence, clinical significance and 
treatment. Sleep Med Rev2006 Jun;10(3):169-77. 
28. Bjorvatn B, Leissner L, Ulfberg J, Gyring J, Karlsborg M, Regeur L, et al. 
Prevalence, severity and risk factors of restless legs syndrome in the general adult 
population in two Scandinavian countries. Sleep Med2005 Jul;6(4):307-12. 
29. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of 
restless legs syndrome in the general population. Arch Intern Med2004 Jan 
26;164(2):196-202. 
30. Mizuno S, Miyaoka T, Inagaki T, Horiguchi J. Prevalence of restless legs 
syndrome in non-institutionalized Japanese elderly. Psychiatry Clin Neurosci2005 
Aug;59(4):461-5. 
31. Sevim S, Dogu O, Camdeviren H, Bugdayci R, Sasmaz T, Kaleagasi H, et al. 
Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. 
Neurology2003 Dec 9;61(11):1562-9. 
 69 
32. Kotagal S, Silber MH. Childhood-onset restless legs syndrome. Ann Neurol2004 
Dec;56(6):803-7. 
33. Clemens S, Rye D, Hochman S. Restless legs syndrome: revisiting the dopamine 
hypothesis from the spinal cord perspective. Neurology2006 Jul 11;67(1):125-30. 
34. Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov 
Disord2007;22 Suppl 18:S440-8. 
35. Tergau F, Wischer S, Paulus W. Motor system excitability in patients with 
restless legs syndrome. Neurology1999 Mar 23;52(5):1060-3. 
36. Hening WA CS. Restless Legs Syndrome E-book. Elsevier Health 
Sciences2009. 
37. Barriere G, Cazalets JR, Bioulac B, Tison F, Ghorayeb I. The restless legs 
syndrome. Prog Neurobiol2005 Oct;77(3):139-65. 
38. Unrath A, Juengling FD, Schork M, Kassubek J. Cortical grey matter alterations 
in idiopathic restless legs syndrome: An optimized voxel-based morphometry study. 
Mov Disord2007 Sep 15;22(12):1751-6. 
39. Rizzo G, Manners D, Vetrugno R, Tonon C, Malucelli E, Plazzi G, et al. 
Combined brain voxel-based morphometry and diffusion tensor imaging study in 
idiopathic Restless Legs Syndrome patients. Eur J Neurol Jul;19(7):1045-9. 
40. Bucher SF, Seelos KC, Oertel WH, Reiser M, Trenkwalder C. Cerebral 
generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol1997 
May;41(5):639-45. 
41. Esteves AM, de Mello MT, Lancellotti CL, Natal CL, Tufik S. Occurrence of 
limb movement during sleep in rats with spinal cord injury. Brain Res2004 Aug 
13;1017(1-2):32-8. 
42. Bara-Jimenez W, Aksu M, Graham B, Sato S, Hallett M. Periodic limb 
movements in sleep: state-dependent excitability of the spinal flexor reflex. 
Neurology2000 Apr 25;54(8):1609-16. 
43. Stiasny-Kolster K, Magerl W, Oertel WH, Moller JC, Treede RD. Static 
mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs 
syndrome. Brain2004 Apr;127(Pt 4):773-82. 
44. Paulus W, Dowling P, Rijsman R, Stiasny-Kolster K, Trenkwalder C. Update of 
the pathophysiology of the restless-legs-syndrome. Mov Disord2007;22 Suppl 18:S431-
9. 
45. Schomburg ED, Steffens H. Comparative analysis of L-DOPA actions on 
nociceptive and non-nociceptive spinal reflex pathways in the cat. Neurosci Res1998 
Aug;31(4):307-16. 
46. Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-
hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model 
for restless legs syndrome. Mov Disord2000 Jan;15(1):154-8. 
47. Barraud Q, Obeid I, Aubert I, Barriere G, Contamin H, McGuire S, et al. 
Neuroanatomical study of the A11 diencephalospinal pathway in the non-human 
primate. PLoS One;5(10):e13306. 
48. Clemens S, Hochman S. Conversion of the modulatory actions of dopamine on 
spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J 
Neurosci2004 Dec 15;24(50):11337-45. 
 70 
49. Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M. The treatment 
of restless legs syndrome and periodic limb movement disorder. An American Academy 
of Sleep Medicine Review. Sleep1999 Nov 1;22(7):970-99. 
50. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs 
syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology1999 Mar 
23;52(5):932-7. 
51. Tribl GG, Asenbaum S, Klosch G, Mayer K, Bonelli RM, Auff E, et al. Normal 
IPT and IBZM SPECT in drug naive and levodopa-treated idiopathic restless legs 
syndrome. Neurology2002 Aug 27;59(4):649-50. 
52. Eisensehr I, Wetter TC, Linke R, Noachtar S, von Lindeiner H, Gildehaus FJ, et 
al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic 
restless legs syndrome. Neurology2001 Oct 9;57(7):1307-9. 
53. Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J. SPECT imaging of 
striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with 
periodic leg movements in sleep. J Neurol2002 Feb;249(2):164-70. 
54. Walters AS. Review of receptor agonist and antagonist studies relevant to the 
opiate system in restless legs syndrome. Sleep Med2002 Jul;3(4):301-4. 
55. Mizuno S, Mihara T, Miyaoka T, Inagaki T, Horiguchi J. CSF iron, ferritin and 
transferrin levels in restless legs syndrome. J Sleep Res2005 Mar;14(1):43-7. 
56. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ. MRI measurement of brain 
iron in patients with restless legs syndrome. Neurology2001 Jan 23;56(2):263-5. 
57. Hornyak M, Scholz H, Kiemen A, Kassubek J. Investigating the response to 
intravenous iron in restless legs syndrome: An observational study. Sleep Med 
Jun;13(6):732-5. 
58. Gemignani F, Brindani F, Negrotti A, Vitetta F, Alfieri S, Marbini A. Restless 
legs syndrome and polyneuropathy. Mov Disord2006 Aug;21(8):1254-7. 
59. Polydefkis M, Allen RP, Hauer P, Earley CJ, Griffin JW, McArthur JC. 
Subclinical sensory neuropathy in late-onset restless legs syndrome. Neurology2000 
Oct 24;55(8):1115-21. 
60. Rutkove SB, Matheson JK, Logigian EL. Restless legs syndrome in patients 
with polyneuropathy. Muscle Nerve1996 May;19(5):670-2. 
61. Ondo WG, Vuong KD, Wang Q. Restless legs syndrome in monozygotic twins: 
clinical correlates. Neurology2000 Nov 14;55(9):1404-6. 
62. Kemlink D, Polo O, Montagna P, Provini F, Stiasny-Kolster K, Oertel W, et al. 
Family-based association study of the restless legs syndrome loci 2 and 3 in a European 
population. Mov Disord2007 Jan 15;22(2):207-12. 
63. Winkelmann J, Polo O, Provini F, Nevsimalova S, Kemlink D, Sonka K, et al. 
Genetics of restless legs syndrome (RLS): State-of-the-art and future directions. Mov 
Disord2007;22 Suppl 18:S449-58. 
64. Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. 
Genome-wide association study of restless legs syndrome identifies common variants in 
three genomic regions. Nat Genet2007 Aug;39(8):1000-6. 
65. Vilarino-Guell C, Farrer MJ, Lin SC. A genetic risk factor for periodic limb 
movements in sleep. N Engl J Med2008 Jan 24;358(4):425-7. 
66. Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, Thorgeirsson TE, et 
al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med2007 Aug 
16;357(7):639-47. 
 71 
67. Schormair B, Kemlink D, Roeske D, Eckstein G, Xiong L, Lichtner P, et al. 
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless 
legs syndrome. Nat Genet2008 Aug;40(8):946-8. 
68. Winkelmann J, Czamara D, Schormair B, Knauf F, Schulte EC, Trenkwalder C, 
et al. Genome-wide association study identifies novel restless legs syndrome 
susceptibility loci on 2p14 and 16q12.1. PLoS Genet Jul;7(7):e1002171. 
69. Mercader N, Leonardo E, Azpiazu N, Serrano A, Morata G, Martinez C, et al. 
Conserved regulation of proximodistal limb axis development by Meis1/Hth. 
Nature1999 Nov 25;402(6760):425-9. 
70. Gross MK, Dottori M, Goulding M. Lbx1 specifies somatosensory association 
interneurons in the dorsal spinal cord. Neuron2002 May 16;34(4):535-49. 
71. Uetani N, Chagnon MJ, Kennedy TE, Iwakura Y, Tremblay ML. Mammalian 
motoneuron axon targeting requires receptor protein tyrosine phosphatases sigma and 
delta. J Neurosci2006 May 31;26(22):5872-80. 
72. Schormair B, Plag J, Kaffe M, Gross N, Czamara D, Samtleben W, et al. MEIS1 
and BTBD9: genetic association with restless leg syndrome in end stage renal disease. J 
Med Genet Jul;48(7):462-6. 
73. Gigli GL, Adorati M, Dolso P, Piani A, Valente M, Brotini S, et al. Restless legs 
syndrome in end-stage renal disease. Sleep Med2004 May;5(3):309-15. 
74. Manconi M, Govoni V, De Vito A, Economou NT, Cesnik E, Mollica G, et al. 
Pregnancy as a risk factor for restless legs syndrome. Sleep Med2004 May;5(3):305-8. 
75. Ulfberg J, Nystrom B. Restless legs syndrome in blood donors. Sleep Med2004 
Mar;5(2):115-8. 
76. Auger C, Montplaisir J, Duquette P. Increased frequency of restless legs 
syndrome in a French-Canadian population with multiple sclerosis. Neurology2005 Nov 
22;65(10):1652-3. 
77. Gomez-Choco MJ, Iranzo A, Blanco Y, Graus F, Santamaria J, Saiz A. 
Prevalence of restless legs syndrome and REM sleep behavior disorder in multiple 
sclerosis. Mult Scler2007 Jul;13(6):805-8. 
78. Manconi M, Ferini-Strambi L, Filippi M, Bonanni E, Iudice A, Murri L, et al. 
Multicenter case-control study on restless legs syndrome in multiple sclerosis: the 
REMS study. Sleep2008 Jul;31(7):944-52. 
79. Manconi M, Rocca MA, Ferini-Strambi L, Tortorella P, Agosta F, Comi G, et al. 
Restless legs syndrome is a common finding in multiple sclerosis and correlates with 
cervical cord damage. Mult Scler2008 Jan;14(1):86-93. 
80. Filippi M, Rocca MA, Comi G. The use of quantitative magnetic-resonance-
based techniques to monitor the evolution of multiple sclerosis. Lancet Neurol2003 
Jun;2(6):337-46. 
81. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH. 
Quantitative assessment of MRI lesion load in monitoring the evolution of multiple 
sclerosis. Brain1995 Dec;118 ( Pt 6):1601-12. 
82. Zivadinov R, Stosic M, Cox JL, Ramasamy DP, Dwyer MG. The place of 
conventional MRI and newly emerging MRI techniques in monitoring different aspects 
of treatment outcome. J Neurol2008 Mar;255 Suppl 1:61-74. 
83. Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Brain atrophy in relapsing 
multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. 
Mult Scler2000 Dec;6(6):365-72. 
 72 
84. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. 
Recommended diagnostic criteria for multiple sclerosis: guidelines from the 
International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001 
Jul;50(1):121-7. 
85. Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, et al. 
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the 
ASA cohort. Clin Neurol Neurosurg Mar 6. 
86. Wichmann HE GC, Illig T. MONICA/KORA Study Group. KORA-gen-
resource for population genetics, controls and a broad spectrum of disease phenotypes. 
Gesundheitswesen; 67 Suppl 1: S26-302005. 
87. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. 
PLINK: a tool set for whole-genome association and population-based linkage analyses. 
Am J Hum Genet2007 Sep;81(3):559-75. 
88. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage 
and association genetic mapping studies of complex traits. Bioinformatics2003 
Jan;19(1):149-50. 
89. Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, et 
al. The UCSC Genome Browser Database: update 2006. Nucleic Acids Res2006 Jan 
1;34(Database issue):D590-8. 
90. Consortium. TIH. A second generation human haplotype map of over 3.1 million SNPs. . 
Nature ;449:851-61 2007. 
91. Paulus W, Dowling P, Rijsman R, Stiasny-Kolster K, Trenkwalder C, de Weerd 
A. Pathophysiological concepts of restless legs syndrome. Mov Disord2007 Jul 
30;22(10):1451-6. 
92. Gross MK, Moran-Rivard L, Velasquez T, Nakatsu MN, Jagla K, Goulding M. 





PhD Candidate’s publications list: IF in total 45.6 
A. Publications in extenso, which form the basis of the PhD thesis  
1. Kemlink D, Polo O, Frauscher B, Gschliesser V, Högl B, Poewe W, Vodicka P, 
Vavrova J, Sonka K, Nevsimalova S, Schormair B, Lichtner P, Silander K, Peltonen L, 
Gieger C, Wichmann HE, Zimprich A, Roeske D, Müller-Myhsok B, Meitinger T, 
Winkelmann J. Replication of Restless Legs Syndrome Loci in Three European 
Populations. J Med Genet. 2009 Mar 10. 46(5):315–8 IF = 5.5 Attachment B 
2. Vávrová J, Kemlink D, Sonka K, Havrdová E, Horáková D, Pardini B, Müller-
Myhsok B, Winkelmann J. Restless legs syndrome in Czech patients with multiple 
sclerosis: An epidemiological and genetic study. Sleep Med. 2012 May 18. [Epub ahead 
of print] IF = 3.4 – Attachment A 
3. Winkelmann J, Czamara D, Schormair B, Knauf F, Schulte EC, Trenkwalder C, 
Dauvilliers Y, Polo O, Högl B, Berger K, Fuhs A, Gross N, Stiasny-Kolster K, Oertel 
W, Bachmann CG, Paulus W, Xiong L, Montplaisir J, Rouleau GA, Fietze I, Vávrová J, 
Kemlink D, Sonka K, Nevsimalova S, Lin SC, Wszolek Z, Vilariño-Güell C, Farrer MJ, 
Gschliesser V, Frauscher B, Falkenstetter T, Poewe W, Allen RP, Earley CJ, Ondo WG, 
Le WD, Spieler D, Kaffe M, Zimprich A, Kettunen J, Perola M, Silander K, Cournu-
Rebeix I, Francavilla M, Fontenille C, Fontaine B, Vodicka P, Prokisch H, Lichtner P, 
Peppard P, Faraco J, Mignot E, Gieger C, Illig T, Wichmann HE, Müller-Myhsok B, 
Meitinger T. Genome-wide association study identifies novel restless legs syndrome 
susceptibility loci on 2p14 and 16q12.1. PLoS Genet. 2011 Jul;7(7):e1002171. Epub 
2011 Jul 14. IF = 9.5 Attachment D 
4. Schormair B & Kemlink D, Roeske D, Eckstein G, Xiong L, Lichtner P, Ripke S, 
Trenkwalder C, Zimprich A, Stiasny-Kolster K, Oertel W, Bachmann CG, Paulus W, 
Högl B, Frauscher B, Gschliesser V, Poewe W, Peglau I, Vodicka P, Vávrová J, Sonka 
K, Nevsimalova S, Montplaisir J, Turecki G, Rouleau G, Gieger C, Illig T, Wichmann 
HE, Holsboer F, Müller-Myhsok B, Meitinger T, Winkelmann J.PTPRD (protein 
tyrosine phosphatase receptor type delta) is associated with restless legs syndrome.Nat 
Genet. 2008 Aug;40(8):946–8. IF 25.5. Attachment C 
 
B. Publications in extenso which are not related to the thesis topic with IF 
Volná J, Kemlink D, Kalousová M, Vávrová J, Majerová V, Mestek O, Svarcová J, 
Sonka K, Zima T. Biochemical oxidative stress-related markers in patients with 
obstructive sleep apnea. Med Sci Monit. 2011 Sep;17(9):CR491–7. IF = 1.7. 
 
C. Publications in extenso which are not related to the thesis topic without IF  
Sonka K, Fialová L, Volná J, Jiroutek P, Vávrová J, Kemlink D, Pretl M, Kalousová   








ATTACHMENT A  
  
 
 
 
 75 
 76 
 77 
 78 
 
ATTACHMENT B 
 79 
 80 
 81 
 
 82 
ATTACHMENT C 
 
 
 83 
 84 
 85 
 
ATTACHMENT D 
 
 86 
 87 
 88 
 
 89 
 90 
 91 
 92 
 93 
 94 
 
